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1 GENERAL INTRODUCTION 
 
 
The prevalence of overweight and obesity has been increasing markedly over the 
past two decades, and obesity is now regarded as a global epidemic affecting both, 
adults and children [BAYS, 2004; GALE et al., 2004; OGDEN et al., 2006; 
RONNETT et al., 2005; WANG et al., 2006]. The World Health Organization 
(WHO) has declared overweight as one of the top ten risk conditions in the world 
and one of the top 5 in developed countries [WHO, 2006]. Increased mortality and 
significant morbidity are directly associated with obesity, mainly due to  
cardiovascular diseases (hypertension, coronary heart disease), metabolic 
disorders (Type 2 diabetes mellitus (T2DM), hyperlipidemia and insulin resistance), 
as well as respiratory diseases, gastrointestinal disorders (fatty liver and cirrhosis), 
and some cancers (cervical, breast, gallbladder and colon) [CALLE et al., 2004; 
CROWLEY, 2008; FLEGAL et al., 2005; NAMMI et al., 2004; WILBORN et al., 
2005]. The basic cause of overweight and obesity is an imbalance between energy 
intake (EI) and energy expenditure (EE), which leads to abnormal or excessive fat 
accumulation in adipose tissue in form of triglycerides (TG) [CAMPFIELD et al., 
1998; HILL et al., 2003; MORTON et al., 2006; NAMMI et al., 2004]. However, the 
relationship between TG synthesis and the development of obesity has not been 
critically examined yet. Specifically, it is still unclear whether inhibition of TG 
synthesis might be a feasible strategy for the treatment of obesity and T2DM 
[CHEN et al., 2000; SHI et al., 2004]. Over the past decade some studies about the 
biology of TG synthesis and the roles of the main enzymes that are involved in lipid 
metabolism were performed and attention was drawn to Acyl CoA:diacylglycerol 
acyltransferase 1 (DGAT1), one of two known key enzymes that catalyze the final 
and only committed step in mammalian TG synthesis [CASES et al., 1998]. 
Selective inhibition of DGAT1-mediated TG synthesis may be an approach to 
treating hypertriglyceridemia or obesity in humans [CASES et al., 1998]. Thus, it 
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has been shown that genetic DGAT1 deficiency in mice makes mice resistant to 
diet-induced obesity and leads to increased leptin sensitivity, to increased energy 
expenditure and to improved glucose sensitivity [CHEN et al., 2002a]. However, 
the effects of a pharmacological inhibition of DGAT1 have not been systematically 
investigated yet. Some patent documentations have described weight loss with 
pharmacological DGAT1 inhibition in rodents that is associated with decreased 
food intake [ZHAO et al., 2008], but the mechanisms and the generality of this 
eating-inhibitory effect remain unclear. 
 
In this thesis I performed three experiments to address these open questions. The 
specific research aims were 1) to determine whether intragastric infusions of a 
DGAT1-inhibitor (DGAT1i01) can inhibit eating in chow-fed or high fat diet (HFD)-
fed rats, respectively; 2) to investigate the effects of intragastric infusion of a 
DGAT1i01 on serum and plasma metabolites in HFD fed rats and 3) to determine 
whether enhanced fatty acid oxidation in small intestinal enterocytes is a possible 
mechanism for the eating-inhibitory effect after intragastric infusion of DGAT1i01. 
The molecular DGAT1i01 used in all three experiments was provided by 
AstraZeneca. 
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2 LITERATURE SURVEY 
 
2.1 The control of food intake 
 
Food intake (FI) provides energy, all the macronutrients, vitamins, minerals, and a 
variable amount of water. Energy intake and energy expenditure, in the form of 
cellular metabolism and exercise, are precisely coupled over long time intervals in 
healthy adults resulting in stable body fat stores [WOODS et al., 2000]. The 
composition and amount of food that we eat varies from meal to meal and from day 
to day [SCHWARTZ et al., 2000; WOODS, 2004a]. Changes in food intake are 
more often due to changes in meal size rather than frequency [WOODS et al., 
2000]. Satiation, i.e., the process that leads to meal termination, results from the 
coordinated interaction of neural and humoral signals that emanate from the gut in 
response to mechanical and chemical stimuli of ingested food (gastrointestinal 
signals, e.g. CCK, see below), and signals generated in proportion to body fat 
mass (adiposity signals, e.g. leptin and insulin, see below) [CUMMINGS et al., 
2007; GALE et al., 2004; KENNEDY, 1953; SCHWARTZ et al., 2000; WOODS et 
al., 1998]. These signals cause changes in the neuronal activity in several brain 
areas, such as the nucleus of the solitary tract (NTS) in the hindbrain and different 
nuclei  in the hypothalamus that control energy homeostasis (see Chap. 2.1.3) 
[SCHWARTZ et al., 2000; WOODS et al., 1998; WOODS et al., 2000]. 
Energy homeostasis is achieved when anabolic and catabolic effects are in 
balance over long periods of time (see Figure 2.1) [WOODS et al., 1998]. Short-
term gastrointestinal signals that are acutely affected by ingested nutrients and that 
influence individual meals, and long-term adiposity hormones, such as leptin and 
insulin, contribute to the regulation of energy homeostasis [BEGLINGER et al., 
2006; MORTON et al., 2006; SCHWARTZ et al., 2000]. 
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Figure 2.1: The general circuitry underlying the control of food intake and regulation of body 
adiposity. 
[Source: [SCHWARTZ et al., 2000]] 
 
 
Most of the gastrointestinal signals act through specific receptors on peripheral 
nerves (e.g. vagus nerve) connecting the GI tract with neurons in the NTS, an area 
of the caudal brain stem that integrates sensory information from the GI tract and 
abdominal viscera, as well as taste information from the oral cavity [SCHWARTZ et 
al., 2000]. Alternatively, gastrointestinal hormones may reach the hindbrain or 
other brain sites via the circulation [MORTON et al., 2006; WOODS, 2004a]. From 
the hindbrain, the principal central site for the control of meal size [CUMMINGS et 
al., 2007], afferent neural information then passes through the brainstem to the 
hypothalamus (see Figure 2.2), where several nuclei such as the arcuate nucleus 
(Arc), the paraventricular nucleus (PVN), the ventromedial nucleus (VMH), the 
dorsomedial nucleus (DMH), and the lateral hypothalamic area (LHA) are 
implicated in the control of eating (see below Chap. 2.1.3) [HOLST et al., 2004; 
SMITH et al., 2008; WOODS et al., 1998]. 
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Figure 2.2: Hormonal and neural routes involved in regulation of appetite. 
      [Source: adapted from [HOLST et al., 2004]] 
 
 
2.1.1 Gastrointestinal signals in the control of eating 
 
The gastrointestinal (GI) tract is the body’s largest endocrine organ and produces 
about 30 different peptidic hormones, which act on several tissues. GI peptides are 
released from enteroendocrine cells in response to ingested food, e.g. specific 
carbohydrates, fats or proteins, or the mixtures of these macronutrients, or through 
mechanical stimulation such as gastric distension (see Figure 2.3) [COLL et al., 
2007; CUMMINGS et al., 2007; MORTON et al., 2006]. Different GI peptides are 
then secreted from multiple sites in the GI tract, including the stomach, pancreas, 
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proximal small intestine, distal small intestine and colon (see Figure 2.4) 
[CUMMINGS et al., 2007; WOODS, 2004a]. Cholecystokinin (CCK), glucagon-like 
peptide-1 and 2 (GLP-1, GLP-2), peptide tyrosine-tyrosine (PYY) and 
oxyntomodulin (OXM) [reviewed by [COLL et al., 2007; MENDIETA-ZERÓN et al., 
2008; SMITH et al., 2008] are peptides which inhibit eating, whereas ghrelin is the 
only GI peptide that stimulates eating [CUMMINGS, 2006; HOLST et al., 2004; 
WREN et al., 2001]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Topography of enteroendocrine 
cells and absorptive enterocytes on a villus 
within the intestinal wall. 
[Source: CUMMINGS and OVERDUIN, 2007] 
 
Figure 2.4:  Principal sites of synthesis of GI 
peptides implicated in the control of FI. 
[Source: CUMMINGS and OVERDUIN, 2007] 
 
2.1.1.1 Cholecystokinin (CCK) 
 
CCK is the first described and most studied GI peptide that acts as a postprandial 
satiation signal. It is secreted in response to digested foods, mainly lipids 
(especially long-chain free fatty acids) (reviewed by [BEGLINGER et al., 2004]) 
and proteins. CCK exists in several molecular forms, primarily CCK-8, CCK-33, 
CCK-39 and CCK-58 in rats. CCK is produced by I-cells in the duodenal and 
jejunal mucosa, as well as in the central nervous system (CCK-4) [COLL et al., 
2007; CUMMINGS et al., 2007]. CCK peptides interact with two G-protein coupled 
receptors termed CCK1 (formerly known as CCK-A, for ‘alimentary’) and CCK2 
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(formerly known as CCK-B, for ‘brain’). Both receptors are widely expressed in the 
central nervous system (CNS) and in the periphery (GI system). The key receptors 
for the reduction of FI, the CCK1-receptors, are expressed on sensory fibers of the 
vagus nerve innervating the tissue around the pyloric sphincter and the proximal 
duodenum. The CCK signal carried in the vagus nerve enters the hindbrain and 
reaches the NTS (reviewed by  [CUMMINGS et al., 2007; MENDIETA-ZERÓN et 
al., 2008]). The physiological relevance of CCK’s satiating effect has been 
confirmed in humans, in whom the carboxy-terminal octapeptide CCK-8 reduces FI 
and meal duration [BEGLINGER et al., 2004]. CCK is considered as a short-acting 
satiation signal because its anorectic effect is short-lived and undetectable if the 
peptide is administered more than 15 min prior to the start of a meal. By increasing 
doses of CCK a greater decrease in FI is obtained [GIBBS et al., 1973]. CCK also 
slows down gastric emptying, thereby prolonging postprandial gastric distension 
(reviewed by [BEGLINGER et al., 2004]).  
 
2.1.1.2 Glucagon-like peptide-1 (GLP-1) 
 
GLP-1 is a peptide product of the gene encoding preproglucagon which is widely 
expressed in the gut, pancreas and NTS [BEGLINGER et al., 2006; COLL et al., 
2007]. It is synthesized in two major molecular forms, as GLP-1(7-36)amide (the 
most common circulating form) and as GLP-1(7-37)amide (reviewed by 
[DRUCKER, 2006; GUTZWILLER et al., 2004; MENDIETA-ZERÓN et al., 2008]). 
GLP-1 is released primarily by L-cells in the distal small intestine and colon, where 
it co localizes with OXM, which is also produced from the preproglucagon gene in 
the intestine and brain, and PYY (see below) [BEGLINGER et al., 2006; COLL et 
al., 2007; CUMMINGS et al., 2007; SMALL et al., 2004]. Ingested nutrients, 
especially free fatty acids (FFA) and carbohydrates, stimulate GLP-1 secretion 
rapidly within minutes by indirect, duodenally activated neurohumoral mechanisms, 
as well as by direct contact within the L-cells of the distal intestine, which is 
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temporally delayed [BRUBAKER, 2006]. The release of GLP-1 initiates a decrease 
in FI and an inhibition of gastric emptying, and it enhances the glucose-dependent 
insulin release from the pancreatic B cells (insulinotropic effect). GLP-1 also 
enhances insulin biosynthesis, thereby replenishing insulin stores, and lowers 
glucose via inhibition of glucagon secretion from pancreatic islet α cells (reviewed 
by [BRUBAKER, 2006; CUMMINGS et al., 2007; DRUCKER, 2006]). These 
pleiotropic and clinically relevant actions of GLP-1 have spurred the development 
of GLP-1 receptor agonists (e.g. exendin-4), or agents that reduce GLP-1 
degradation (e.g. dipeptidyl peptidase-4 (DPP-4) inhibitors) that are promising 
therapeutics for the treatment of T2DM [DRUCKER, 2006]. Many studies in rodent 
models of diabetes as well as in patients with T2DM have demonstrated that GLP-
1 receptor (GLP-1R) agonists and DPP-4 inhibitors lead to significant reductions in 
glycemia and HbA1c levels (reviewed by [BRUBAKER, 2006]). The effect of GLP-1 
on eating may be mediated via a heptahelical G-protein-coupled GLP-1R) 
expressed in hypothalamus, brainstem and periphery (pancreatic islets, lung, 
stomach and duodenum). GLP-1R activation leads to increases in intracellular 
Ca2+ and is coupled to activation of cyclic adenosine 3´,5´-monophosphate/protein 
kinase A (cAMP/PKA)-dependent signaling as well as activation of PKC, 
phospatidylinositol-3 kinase (PI-3K) and MAPK signaling pathways (reviewed by 
[BAGGIO et al., 2007; BEGLINGER et al., 2006; BRUBAKER, 2006]).  
 
2.1.1.3 Peptide tyrosine-tyrosine (PYY) 
 
Peptide PYY exists in two main forms, PYY1-36 and the active anorectic form PYY3-
36, and is a member of the pancreatic polypeptide family that also includes 
pancreatic polypeptide (PP; a pancreatic satiation peptide) and neuropeptide Y 
(NPY; a orexigenic hypothalamic neuropeptide) [CUMMINGS et al., 2007; SMITH 
et al., 2008].  PYY is mainly produced by the same cells in the distal-intestinal cells 
(ileum, colon and rectum) that secrete GLP-1, and its secretion is correlated with 
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caloric intake, with larger release after ingestion of larger meals. Fat is the 
strongest macronutrient stimulus for PYY release, followed by carbohydrates 
(reviewed by [CUMMINGS et al., 2007; MENDIETA-ZERÓN et al., 2008; SMALL et 
al., 2004]). Receptors that mediate the effects of PYY belong to the NPY receptor 
family and include the Y1, Y2, Y4, Y5, and Y6 receptors [BEGLINGER et al., 
2006]. PYY1-36 binds Y1R, Y2R, Y4R and Y5R while PYY3-36 binds with high affinity 
to the arcuate Y2R, and with lower affinity to the Y1R and Y5R [SMITH et al., 
2008]. Systemic PYY crosses the blood-brain barrier (BBB) and probably exerts its 
activation via the Y2R in the hypothalamic Arc. In the hypothalamus, the Y2R is a 
presynaptic autoinhibitory receptor on orexigenic neurons that express both NPY 
and agouti-related protein (AgRP). Inhibition of these AgRP/NPY neurons through 
Y2R leads to a disinhibition of adjacent anorectic pro-opiomelanocortin (POMC) 
neurons, which are inhibited by AgRP/NPY neurons. PYY therefore inhibits eating 
[BATTERHAM et al., 2002]. Peripheral administration of PYY3-36 has been shown 
to delay gastric emptying [MORAN et al., 2005] and secretion, and it decreases FI 
and weight gain in rodents, primates and humans. The appetite inhibitory effect 
was also seen with a Y2R-specific agonist and was absent in the Y2R-deficient 
mouse [BATTERHAM et al., 2002; MORAN et al., 2005]. However, central 
administration of either PYY1-36 or PYY3-36  potently increases FI [HAGAN, 2002]. 
 
2.1.1.4 Apolipoprotein A-IV (apo A-IV) 
 
Apo A-IV is a circulating glycoprotein (molecular weight of 46-kDa) secreted 
primarily by the small intestine in humans and rodents, in which small amounts of 
apo A-IV are also secreted from the liver. In the intestine, apo A-IV is released in 
association with chylomicrons during fat absorption. It is used to package digested 
lipids for their transit through the lymphatics to the blood (reviewed by 
[CUMMINGS et al., 2007; GOTOH et al., 2006; TSO et al., 2004]). Apo A-IV is also 
synthesized in the hypothalamus, with the Arc having a higher content of apo A-IV 
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relative to other areas of the CNS [LIU et al., 2001; SHEN et al., 2008; TSO et al., 
2004]. It has been demonstrated that the level of apo A-IV messenger RNA 
(mRNA) in the hypothalamus is influenced by an animal’s nutritional status. Fasting 
causes a marked reduction in apo A-IV gene expression in both, the hypothalamus 
and jejunum. However, lipid re-feeding rapidly restores hypothalamic apo A-IV 
mRNA levels to the levels observed in ad libitum (ad lib) fed animals [LIU et al., 
2001; SHEN et al., 2008; TSO et al., 2004]. Systemic or intracerebroventricular 
(ICV) administration of apo A-IV significantly inhibits food intake and body weight of 
rats in a dose-dependent manner [FUJIMOTO et al., 1993], whereas apo A-IV-
specific antibodies (goat anti-rat apo A-IV serum), infused into the third cerebral 
ventricle, elicit eating in rats [FUJIMOTO et al., 1993]. It has been demonstrated 
that central apo A-IV reduces FI by potentiating the anorectic effect of central 
melanocortin (MC) agonists by acting downstream of the Arc, and that there is a 
synergism between apo A-IV and MC type 3 and 4 receptor, (MC3/4-R) signaling 
that causes anorexia [GOTOH et al., 2006].  Because both, intestinal and 
hypothalamic apo A-IV are regulated by fat absorption but not by carbohydrates, 
apo A-IV is hypothesized to represent a link between short- and long-term 
regulation of lipid-related energy balance (EB) [reviewed by [TSO et al., 2001]]. 
Apo A-IV may also interact with other metabolic signals involved in the regulation 
of energy homeostasis such as leptin and insulin (see below), which contribute to 
the regulation of body adiposity [LIU et al., 2001]. 
 
2.1.1.5 Ghrelin 
 
Ghrelin, an acylated 28 amino acid peptide, was first described in 1999 as the 
endogenous ligand of the growth hormone (GH) secretagogue receptor (GHS-R; 
‘ghrelin receptor’), which is expressed in the Arc and other hypothalamic and brain 
stem nuclei, as well as in peripheral tissues (reviewed by [COLL et al., 2007; 
CUMMINGS, 2006; MENDIETA-ZERÓN et al., 2008; SMALL et al., 2004]). Ghrelin 
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is produced and secreted primarily by the gut, in the gastric oxyntic cells (A/X cells) 
in the fundus of the stomach, as well as by proximal small intestinal cells (reviewed 
by [CUMMINGS, 2006; MENDIETA-ZERÓN et al., 2008]). Ghrelin is the only 
peripheral orexigenic hormone known to date (for review, see [CUMMINGS, 2006; 
GEARY, 2004]). Peripheral administration of ghrelin potentially increases FI in 
diverse species, including humans [TSCHOP et al., 2000; WREN et al., 2001]. 
Ghrelin also stimulates gastric acid secretion and motility and the release of GH 
(reviewed by [CUMMINGS, 2006; HELLSTROM et al., 2004; MENDIETA-ZERÓN 
et al., 2008]). Ghrelin is normally secreted prior to meals [CUMMINGS, 2006; 
HOLST et al., 2004; MENDIETA-ZERÓN et al., 2008], and its levels decrease 
during eating or when nutrients are infused into the stomach [SHIIYA et al., 2002] 
These findings suggest that plasma ghrelin reflects an acute feeding state and may 
also serve as an indicator of short-term EB [SHIIYA et al., 2002]. Chronic 
peripheral ghrelin administration leads to significant increases in cumulative FI and 
body weight (BW) gain, with the latter being mainly the result of increased fat 
deposition with some contribution by decreased energy expenditure [TSCHOP et 
al., 2000]. Beyond its proposed role in the short-term control of eating, ghrelin also 
appears to play a role in the long-term BW regulation. Interestingly, basal ghrelin 
levels are also decreased in obese humans and increased in weight loss [TSCHOP 
et al., 2001]. Furthermore it is reported that fasting plasma ghrelin concentration 
negatively correlates with percentage of body fat, and fasting insulin and leptin 
concentration [CUMMINGS, 2006; TSCHOP et al., 2001]. In addition to being 
produced in the stomach, ghrelin may also be produced in the brain, playing an 
important role in signaling hypothalamic Arc neurons, which co-express the potent 
orexigenic neuropeptides, NPY and AgRP (blocking the MC3 and MC4 receptors) 
[CUMMINGS, 2006; HOLST et al., 2004; TSCHOP et al., 2000]. Almost all Arc 
NPY/AgRP neurons express ghrelin receptors and respond to ghrelin by increasing 
their firing rate [CUMMINGS, 2006; MONDAL et al., 2005; NOGUEIRAS et al., 
2008]. The anorectic pools of Arc neurons (POMC/CART (cocaine and 
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amphetamine-related transcript) do not posses ghrelin receptors [HOLST et al., 
2004] (for effects of the NPY/AgRP activation see Chap. 2.1.3). 
 
2.1.2 Adiposity signals in the control of eating and BW 
 
Circulating signals generated in proportion to body fat stores (adiposity signals) 
influence FI and EE in a coordinated manner to keep body fat and, hence, body 
weight stable. This concept of ‘lipostasis’ was proposed by Gordon Kennedy 
[KENNEDY, 1953] about 50 years ago. The two best known long-acting adiposity 
signals are the pancreatic hormone insulin and the adipose tissue hormone leptin, 
both acting in the brain, with the hypothalamus being a critical CNS site for their 
catabolic effects. A change in the their plasma levels indicates a state of altered 
energy homeostasis and adiposity, and the brain responds by adjusting FI and EE 
to restore adipose tissue mass to a regulated level [BASKIN et al., 1999].  
 
2.1.2.1 Leptin 
 
Leptin, the obese (ob) gene product [ZHANG et al., 1994], is a cytokine-like, 
glycosylated protein, predominantly synthesized and secreted by adipose tissue. 
Lower levels of expression are also detected in the hypothalamus, pituitary, 
placenta, skeletal muscle, and gastric and mammary epithelia (reviewed by [GALE 
et al., 2004; SCHWARTZ et al., 2000]). Leptin is secreted in direct proportion to the 
amount of fat stored in the adipocytes. Thus, circulating leptin increases as an 
individual becomes more obese. However, obesity is often accompanied by ‘leptin 
resistance’, which presumably underlies the failure to regulate energy stores 
[TARTAGLIA et al., 1995]. Humans with a genetic lack of leptin are hyperphagic 
and severely obese and respond strongly to leptin administration [COLL et al., 
2007].  
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The importance of leptin as an adiposity signal to the brain has been discovered in 
animal models, such as the ob/ob mice, which have a mutation in the ob gene 
rendering them unable to synthesize leptin [ZHANG et al., 1994]. Other animals 
have genetic mutations that comprise functioning of the leptin receptor (db/db mice 
(diabetes mutation) and fatty Zucker, fa/fa rats) [CHUA, JR. et al., 1996]. The 
phenotype of db/db mice and fa/fa rats, which includes severe, early onset obesity 
and extreme insulin resistance, is identical to that of ob/ob mice. Central 
administration of small amounts of leptin reverses these syndromes in ob/ob mice 
(for reviews see [WOODS et al., 2000]) without causing signs of illness [WOODS 
et al., 2001]. Leptin enters the CNS by a saturable, receptor-mediated transport 
across brain capillary endothelial cells. The leptin concentration of human 
cerebrospinal fluid therefore correlates directly with plasma concentrations 
[WOODS et al., 1998]. Numerous studies support the hypothesis that the activation 
of hypothalamic receptors [SCHWARTZ et al., 2000] is a major pathway for leptin’s 
catabolic effects on EB.  
Leptin inhibits Arc neurons containing (orexigenic) 
peptides, NPY and the MCR antagonist AgRP, 
whereas POMC/CART neurons are stimulated 
[COLL et al., 2007; WOODS et al., 2001]. This 
induces the synthesis of α-melanocyte stimulating 
hormone (α-MSH), which is cleaved from the 
POMC precursor molecule. It exerts its effect by 
binding to MC3R and MC4R in the PVN, which 
engages the MC circuitry that decreases FI and 
increases EE [SCHWARTZ et al., 2000]. Thus, 
leptin impacts the EB equation by decreasing FI 
and increasing EE, which in turn causes a 
decrease in BW. 
Figure 2.5: Control of food intake 
by the hypothalamic leptin-
melanocortin pathway. 
[Source: [SCHWARTZ et al., 2000]] 
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2.1.2.2 Insulin 
 
Insulin is secreted from pancreatic β-cells in response to sensory stimuli (cephalic 
phase insulin release), GI peptides, and increases of glucose or certain amino 
acids. The basal plasma and cerebrospinal fluid (CSF) insulin levels are directly 
correlated with body adiposity [WOODS et al., 2001]. Obese individuals have 
higher basal and CSF insulin levels than lean individuals [WOODS et al., 2001]. As 
an adiposity signal, insulin crosses the BBB via a saturable, receptor-mediated 
transport mechanism that involves insulin receptors; they are highly expressed in 
the hypothalamic Arc cells that synthesize NPY and POMC [BASKIN et al., 1999; 
BENOIT et al., 2002; SCHWARTZ et al., 2000; WOODS et al., 1998]. Insulin acts 
through the same hypothalamic neuropeptide systems as leptin to control FI and to 
regulate BW [BENOIT et al., 2002]. Central administration (ICV) of exogenous 
insulin results in a dose-dependent decrease in FI [BENOIT et al., 2002] and BW 
[OBICI et al., 2002; WOODS et al., 2001], and conversely, the chronic central 
administration of insulin antibodies leads to increased FI and BW (reviewed by 
[BENOIT et al., 2002]). Consistent with this, a selective decrease in insulin receptor 
(IR) expression in a discrete region of the hypothalamus, generated by ICV 
infusion of antisense oligodeoxy-nucleotide (ODN) designed to blunt the 
expression of the IR protein in rat hypothalamic areas, results in a rapid and 
significant hyperphagia and rapid onset of hepatic insulin resistance [OBICI et al., 
2002; WOODS et al., 1998]. 
 
According to the concept of the regulation of energy homeostasis by leptin and 
insulin, a negative EB (low insulin and leptin) results in a disinhibition of the 
anabolic pathway and an inhibition of the catabolic pathway, a condition that favors 
increased FI and energy storage. Conversely, during states of positive EB (high 
insulin and leptin) the opposite is observed, i.e., inhibited anabolic and disinhibited 
catabolic pathways. In this state, FI and the size of the adipose mass are reduced 
(see Figure 2.6; [WOODS et al., 1998]). Hence, insulin and leptin share many 
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common activities regarding the regulation of energy homeostasis, suggesting that 
both act mainly in the hypothalamic Arc to control caloric intake and expenditure 
[BASKIN et al., 1999; BENOIT et al., 2002]. 
 
 
Figure 2.6: The general circuitry underlying the regulation of body weight. 
       [Source: [WOODS et al., 1998]] 
 
2.1.3 Integration of peripheral and central signals within the hypothalamic 
arcuate nucleus 
 
Integration of peripheral and central anabolic and catabolic inputs within the 
hypothalamic Arc is believed to be central to the maintenance of EB [VAN DEN 
TOP et al., 2006; WOODS, 2004a]. Consistent with this, administration of leptin 
and insulin enhances the central sensitivity to input from short-acting peripheral 
satiation signals such as CCK, resulting in smaller meals that have the cumulative 
effect of reducing BW [BASKIN et al., 1999; MORTON et al., 2006; SCHWARTZ et 
al., 2000; WOODS, 2004a]. These findings suggest that hypothalamic pathways 
that are sensitive to leptin and insulin have anatomical connections with caudal 
brainstem neurons, e.g., with the NTS, which respond to meal-related signals and 
control meal size [BASKIN et al., 1999]. The site of integration of meal-related 
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signals with other signals that influence meal size begins within individual vagal 
afferent fibers and continues into the NTS in the hindbrain, where meal size is 
finally determined [WOODS, 2004a; WOODS, 2004b]. At the same time, the Arc 
continuously receives signals related to adiposity as well as information concerning 
ongoing meals from the hindbrain, and it also contains neurons that monitor 
ongoing metabolism directly (see  Figure 2.7) [WOODS, 2004a]. Hence, the Arc 
contains multiple neuronal systems with different populations of cells, which are 
important in the regulation of energy homeostasis [WILLIAMS et al., 2001; 
WOODS et al., 1998]. 
 
 
Figure 2.7: Neuroanatomical model of pathways by which the adiposity signals leptin and insulin 
interact with central autonomic circuits controlling meal size. 
[Source: [SCHWARTZ et al., 2000]] 
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Figure 2.8: NPY/AgRP and POMC neurons act as an 
interconnected circuit. 
[Source: modified from [SCHWARTZ et al., 2002]] 
One of these cell populations 
contains two neuropeptides, i.e. 
NPY and AgRP, which are 
powerful stimulators of eating 
behavior in animals, whereas the 
other contains POMC, which is 
split into α-MSH; this then inhibits 
eating by acting on MC4R (see 
Figure 2.8; reviewed by [GALE et 
al., 2004; HELLSTROM et al., 
2004; SCHWARTZ et al., 2000]). 
 
Both subsets of neurons project to adjacent hypothalamic areas including the PVN, 
where neurons that reduce FI are concentrated (anorexigenic), and the LHA as 
well as the perifornical area (PFA), which contain neurons that stimulate FI 
(orexigenic) [MORTON et al., 2006; SCHWARTZ et al., 2000]. The PVN and LHA 
have direct descending connections to caudal brainstem centers that process food-
related signals (see Figure 2.7; [BASKIN et al., 1999; SCHWARTZ et al., 2000]). 
 
2.1.4 Metabolic signals in the control of eating  
 
Metabolic signals generated by the supply and utilization of metabolic fuels 
influence food choice and how much food is consumed in the short-term. Metabolic 
signals also determine FI in the long-term and are important in maintaining EB over 
a nutritionally significant time interval [FRIEDMAN et al., 2005]. Hence, nutrients 
such as glucose, FA, and amino acids (AA) act as signaling molecules informing 
the CNS about the energy status of the organism [SANDOVAL et al., 2008].  
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2.1.4.1 Signals derived from glucose 
 
In 1955 Mayer [MAYER, 1955] proposed that the CNS uses glucose as a signal to 
control FI (‘glucostatic theory’). According to this theory, hypo- or hyperglycemia 
should induce changes in eating behavior (hunger or satiety). Consistent with the 
glucostatic theory, a brief pre-meal decline in blood glucose levels appears to 
contribute to meal initiation [CAMPFIELD et al., 2003]. Some evidence for a role of 
glucose in the control of FI has been provided by the use of specific glucose 
utilization inhibitors, in particular 2-deoxy-D-glucose. This glucose analog inhibits 
glucose metabolism and potently increases FI (reviewed by [SANDOVAL et al., 
2008]). Stronger evidence for a regulatory role of glucose in eating is derived from 
studies in transgenic mice lacking the glucose-transporter-2 (GLUT-2). These 
GLUT-2-KO mice eat more than corresponding wild type mice and they show an 
increase in orexigenic and a decrease in anorexigenic neuropeptide expression in 
the hypothalamus [BADY et al., 2006]. In fact, there are several glucose-sensing 
neurons present in different regions of the brain, from the hindbrain to the 
hypothalamus (VMH, LHA), that increase or decrease their activity in response to 
glucose [LEVIN, 2006]. Together with peripheral glucose sensors, such as the 
taste buds and the vagal afferents in the hepatic portal vein [HEVENER et al., 
2000], they form a network that monitors glucose availability. Interestingly, glucose 
influences the expression and turnover of anorexigenic POMC and orexigenic 
AgRP/NPY neurons in the Arc (see above) which presumably mediate the effects 
of glucose-sensing on eating. Indeed, POMC neurons are considered as glucose-
excited cells, whereas NPY neurons belong to the glucose-inhibited cells [LEVIN, 
2006; SANDOVAL et al., 2008]. In most of these neurons glucokinase, an enzyme 
that catalyses glucose phosphorylation, which is the rate limiting step in ATP 
production, appears to be the primary regulator of glucose-sensing [LEVIN, 2006]. 
Furthermore, these neurons also respond to peripheral hormones (insulin, leptin; 
see above) which inform the brain about metabolic status and body adiposity. 
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2.1.4.2 Signals derived from fatty acids 
 
Circulating lipids such as TG, glycerol and LCFAs can also be sensed in the CNS 
and appear to be involved in the control of eating and hepatic glucose production. 
In the hypothalamus an energy ‘surfeit’ signal has been proposed to be generated 
by increased cellular LCFA-CoA pools, which activate neural pathways that in turn 
curtail FI and liver glucose production [LAM et al., 2005; MIGRENNE et al., 2007]. 
The physiological relevance and the exact molecular mechanism of this effect are 
still unclear; however, β-oxidation seems to play an important role, and FA 
metabolites such as malonyl- and acyl-CoA may relay their effects [LAM et al., 
2005].  
 
2.1.5 Control of food intake by fatty acid oxidation 
 
In 1986 Scharrer and Langhans [SCHARRER et al., 1986] first demonstrated that 
an inhibition of peripheral fatty acid oxidation (FAO) by mercaptoacetate (MA) 
stimulates eating in rats fed a medium fat diet (18% fat), but not in rats fed a low fat 
diet (3.3% fat). MA inhibits FAO by interfering with the acyl-CoA dehydrogenases 
(EC 1.3.99.3) that catalyze the first step of β-oxidation in the mitochondrial matrix 
[BAUCHE et al., 1981]. These and other results suggest that FAO is involved in the 
control of FI when dietary fat levels are high [SCHARRER et al., 1986]. 
Furthermore, this eating-stimulatory effect of FAO inhibition seems to be signaled 
to the brain by vagal afferents. A role of vagal afferents was suggested early on 
(reviewed by [LEONHARDT et al., 2004]). More recently [BRANDT et al., 2007], 
the failure of MA to stimulate eating in rats after subdiaphragmatic vagal 
deafferentation, a procedure that surgically eliminates all vagal afferents while 
leaving about 50% of the efferents intact, convincingly demonstrated the necessity 
of vagal afferents for the eating-stimulatory effect of MA. Further support for a 
causal relationship between inhibition of fatty acid oxidation and stimulation of 
eating is derived from findings of an increase in food intake in response to 
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administration of other inhibitors of fatty acid oxidation. Thus, Friedman et al. 
[FRIEDMAN et al., 1986], showed an increase in FI in rats fed a HFD using the 
FAO inhibitor methyl palmoxirate (MP; methyl 2-tetradecylglycidate). MP reduces 
FAO by inhibiting carnitine O-palmitoyltransferase 1 (CPT-1; EC 2.3.1.21), the rate-
limiting enzyme for the transport of long-chain FAs into the 
mitochondria [DECLERCQ et al., 1985]. Etomoxir, like MP, inhibits CPT-1 and 
FAO, and also stimulates FI in rats and in humans [HORN et al., 2004; KAHLER et 
al., 1999]. Moreover, etomoxir decreased plasma β-hydroxybutyrate in humans, 
indicating a decrease in hepatic FAO [KAHLER et al., 1999]. Both, MP and 
etomoxir also reduced hepatic energy status (ATP/ADP ratio) and phosphorylation 
potential [HORN et al., 2004]. In contrast to the strong eating-stimulatory effect of 
FAO inhibition, the evidence for an eating-inhibitory effect of FAO stimulation is 
inconsistent and weak. This discrepancy still needs to be explained. 
Thupari et al. [THUPARI et al., 2002] showed that 
intraperitoneally (IP) injected C75 (α-methylene-γ-
butyrolactone), a known inhibitor of fatty acid 
synthase (FAS; EC 2.3.1.85) [KUHAJDA et al., 
2000], increases FAO in adipose tissue and liver in 
spite of high levels of malonyl-CoA, and also 
reduces FI [THUPARI et al., 2002]. The increased 
FAO and ATP levels, which might be due to 
increased CPT-1 activity, led to enhanced cellular 
energy turnover and decreased hepatic fat content 
(see Figure 2.9) [THUPARI et al., 2002]. This 
eating-inhibitory effect of IP C75 is not vagally  
Figure 2.9: Model for C75 action 
on energy metabolism. 
(Tricarboxylic acid cycle (TCA), 
electron transport chain (ETC), 
phosphorylated AMP-activated 
protein kinase (p-AMPK)) 
[Source: [LANDREE et al., 2004]] 
mediated, because total subdiaphragmatic vagotomy or selective 
subdiaphragmatic vagal deafferentation failed to diminish it [MANSOURI et al., 
2008a]. 
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2.2 Dietary fat in the digestive tract 
 
The most important function of the digestive tract is the transformation of energy 
from ingested food into absorbable and usable sources of energy. This process is 
closely linked to the digestion and physicochemical transformation of 
macromolecular nutrients (carbohydrates, triglycerides (TG), proteins) to 
monomers (glucose, AA) or reconstituted aggregates (chylomicrones) and, 
moreover, to the transport of these substrates through the intestinal mucosal cells 
into the blood and the lymphatic system. Dietary fat consists mostly (approximately 
90%) of TGs, and the remaining 10% consist of cholesterol esters, phospholipids, 
and plant sterols (reviewed by  [BUHMAN et al., 2002; FRIEDMAN et al., 1980]). 
 
2.2.1 Digestion and Absorption of dietary fat 
 
Lipid digestion and absorption is a complex process that requires several 
enzymatic components to convert insoluble lipids (nonpolar) into water soluble and 
thus absorbable products [FRIEDMAN et al., 1980]. The absorption of TG by the 
intestine is very efficient because more than 95% of dietary TGs are absorbed 
[MANSBACH et al., 2007; ROS, 2000]. 
 
2.2.1.1 Digestion 
 
Dietary fat digestion is initiated in the stomach, where lipids (mostly TG; see Chap. 
2.2.2) are partially broken down to sn (stereospecific numbering)-1,2-diacylglycerol 
(DAG) and free FAs (FFAs) by lingual and gastric lipase, which accounts for 10-
30% of dietary fat hydrolysis [FRIEDMAN et al., 1980; SHEN et al., 2001; SHI et 
al., 2004]. Subsequently, lipids are formed into large fat globules with hydrophobic 
TG cores surrounded by polar molecules resulting in an initial emulsion (chyme). 
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This emulsion is stabilized by cholesterol (CL; see 
Figure 2.10), phospholipids (PL; predominantly 
phosphatidylcholine (PC); see Figure 2.10), ionized 
proteins and limited amounts of FFAs from the 
hydrolysis of TG by gastric lipase. The emulsification 
of dietary fat is an important precondition for efficient 
hydrolysis by the pancreatic lipase (see below) (for 
review see [ROS, 2000; SHEN et al., 2001; SHI et 
al., 2004]). The digestive process is then completed 
in the lumen of the small intestine (luminal digestion), 
where the emulsion of fat globules is mixed with bile 
salts, molecules that have an amphipathic structure 
[FRIEDMAN et al., 1980] (BS; see Figure 2.10), and 
pancreatic juice, including the pancreatic lipase (EC 
3.1.1.3), the principal lipolytic enzyme, and colipase, 
a cofactor of lipase activity [FRIEDMAN et al., 1980]. 
Pancreatic lipase acts only on the oil-water interface 
and breaks down TG at the position sn-1 and sn-3, 
leading to the formation of 2-MAG and FFAs. 
Colipase first attaches to the aqueous interface of 
 
 
Figure 2.10: Chemical structure 
of cholesterol, phospholipid and 
bile acid. Their hydrophilic 
domains are shown inside 
broken lines. 
[Source: [ROS, 2000]] 
 
TG to maximize exposure to the catalytic site of the pancreatic lipase, and 
subsequently lipase binds to colipase. Adequate concentrations of bile salts must 
be available for effective lipase activity and micellar solubilization [SHEN et al., 
2001; SHIAU, 1981]. PLs are hydrolyzed by the pancreatic phospholipase A2 
(pPLA2) (EC 3.1.1.4) at the sn-2 position, which generates lysophospholipids (e.g. 
lysophosphatidylcholine) and FFAs [SHEN et al., 2001; SHI et al., 2004]. 
Cholesteryl ester must be hydrolyzed first by the pancreatic esterase (EC3.1.1.13) 
before they can be absorbed as free CL [SHEN et al., 2001]. 
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2.2.1.2 Absorption by enterocytes 
 
After digestion, MAG, DAG, FFAs, lysophosphatidic acid (LPA), CL, fat-soluble 
vitamins and BS are assembled to mixed micelles, in which the polar groups 
project into the water phase, whereas the nonpolar hydrocarbons form the center, 
resulting in a high water solubility. These micelles are then absorbed by 
enterocytes via diffusion across the intestinal brush border membrane (see Figure 
2.11a) (reviewed by [ROS, 2000; SHI et al., 2004; SHIAU, 1981]). Monomers of 
FFAs and MAG are also able to cross the microvillous membrane by diffusion and 
active transport, facilitated by transporters, such as intestinal fatty acid binding 
protein (IFABP), CD36 and FA-transport-protein-4 (FATP4) [MANSBACH et al., 
2007; SHI et al., 2004; SHIAU, 1981]. Intracellularly, MAG and FFAs are then 
carried to the endoplasmic reticulum (ER), where they are sequentially re-esterified 
to TG. This process consists predominantly of the acylation from MAG to sn-1,2-
DAG by MAG acyltransferase (MGAT), and the acylation from DAG to TG by 
diacylglycerol acyltranserase (DGAT) (see below, Chap. 2.2.2.2). LPA and CL are 
also acylated to phosphatic acid (PA) and CL ester, respectively, by 1-acylglycerol-
3-phosphate acyltransferase (AGPAT) or acyl-CoA:cholesterol acyltransferase 
(ACAT), respectively. PA is then converted to TG (see Figure 2.11b) [SHEN et al., 
2001; SHI et al., 2004]. 
 
2.2.1.3 Formation of intestinal chylomicrons 
 
CMs are heterogeneous particles, which mainly transport dietary fat in the 
postprandial state. The CM formation begins in the ER lumen and terminates with 
the exit of mature CM from the Golgi complex. Newly synthesized TGs along with 
PLs, CL, and protein from LPs are incorporated into chylomicrons (CM) by a 
sequential multistep process [MANSBACH et al., 2007; SHI et al., 2004; SHIAU, 
1981]. Apolipoprotein B48 (apo B48), synthesized by the rough ER (rER) and the 
microsomal TG transfer protein (MTP), are required for the CM assembly. ApoB48 
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forms stable complexes (dense particles) with PL, CL, and small amounts of TG, 
and is chaperoned by the MTP, it is merged in the smooth ER (sER) with a large 
light particle consisting of neutral lipids (TG and CL esters), and apo A-IV. The 
resulting lipid particles that consist of a core of TG and CL ester, coated by a 
monolayer of PLs, apo B48 and apo A-IV, buds then from the sER as a nascent 
protein transport vesicle. This prechylomicron transport vesicle (PCTV) is able to 
fuse with the Golgi complex, and further, delivers its content into the lumen. Within 
the Golgi lumen, apoprotein AI (apo AI) sticks to the prechylomicrons to create a 
mature CM. The mature CMs are then released from the Golgi complex into the 
intercellular space where they enter the circulation via the lymph system (see 
Figure 2.11). The blood transports the CM to other organs (e.g. liver, muscle and 
adipose tissue) where TG are released again from the CM to be used as a source 
of energy [HUSSAIN, 2000; MANSBACH et al., 2007].  
Figure 2.11: The process of dietary lipid digestion (a) and absorption (b). 
[Source: [SHI et al., 2004]] 
 
2.2.2 TG 
Triglycerides (TGs) (also known as triacylglycerols; 
TAGs) are a heterogeneous group of hydrophobic, 
neutral lipids with a glycerol backbone. The glycerol is 
esterified with three fatty acids (FAs), which can differ in 
chain length (16, 18 and 20 carbons are the most 
common) and degree of unsaturation [FRIEDMAN et 
al., 1980; YEN et al., 2008]. Figure 2.12: Chemical 
structure of a triglycerid. 
[Source: [ROS, 2000]] 
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The primary sources of these FAs are the diet (see Chap. 2.2.1 for intestinal fat 
digestion and absorption) and de novo synthesis, secondary sources are the FA 
released from body stores and those generated by chain elongation and 
desaturation [LEHNER et al., 1996]. 
 
2.2.2.1 Biosynthesis of TG 
 
All humans, animals, plants, bacteria and yeast are capable of synthesizing TG. In 
mammals, TGs are primarily synthesized and secreted in the liver and small 
intestine, while adipocytes predominantly store TGs and release FAs into plasma, 
where they form albumin-bound complexes [COLEMAN et al., 2004; FARESE, JR. 
et al., 2000]. Because of their hydrophobicity, TGs play a major role in dietary fat 
absorption and fat transportation. They are concentrated in cytosolic lipid droplets 
in cells or are found in the plasma incorporated into very-low-density lipoprotein 
(VLDL). TGs are also an essential component of milk [CASES et al., 2001; YEN et 
al., 2008; ZAMMIT, 1996]. The liver plays an important role in the regulation of TG 
synthesis and partitioning, between retention of TG in form of cytosolic lipid 
droplets and secretion. This, on the other hand, is of primary importance in 
determining the rate of VLDL production [OWEN et al., 1997]. 
In eukaryontes, TGs are quantitatively the most important energy storage form in 
muscle and adipose tissue, and they have a crucial function as source of essential 
and non-essential FAs and as a source of precursors for phospholipid biosynthesis 
(e.g. phosphatidylcholine) [COLEMAN et al., 2004]. But an excess accumulation of 
TG in adipocytes or a high level of TG in the bloodstream can be linked to many 
human diseases, such as obesity, T2DM, atherosclerosis, nonalcoholic 
steatohepatitis and pancreatitis. There is also an elevated risk of heart diseases 
and stroke [CASES et al., 2001; UNGER, 2002; YEN et al., 2008]. 
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2.2.2.2 Pathways of TG synthesis 
 
There are two major pathways of TG synthesis in mammalian tissues [CLARK et 
al., 1961]: 1) the glycerol phosphate or phosphatidic acid pathway, associated with 
the liver and adipose tissue, and 2) the monoacylglycerol (MAG) pathway, 
associated with the intestine [LEHNER et al., 1996]. In the glycerol phosphate 
pathway phosphatidate is formed by adding two fatty acyl CoAs to glycerol-3-
phospate. Subsequently, a phosphate is removed from the phosphatidate, 
catalyzed by phosphatidate dephosphorylase, resulting in a diacylglycerol (DAG), 
which can then be joined to a fatty acyl CoA to form TG (see below, Figure 2.14). 
The monoacylglycerol pathway is considered as the main pathway for the TG 
biosynthesis, whereas the phosphatidic acid pathway, representing the de novo 
route to TG formation, accounts for only about 20-30% of formed TG [LEHNER et 
al., 1996]. Both pathways use fatty acyl-coenzymes A (FA CoAs) as acyl donors 
and glycerol (glycerol-3-phosphate and/or dihydroxyacetone phosphate (DHAP)) or 
2-monoacylglycerol (2-MAG), respectively, as acyl acceptor, to produce DAG 
intermediates (see Figure 2.14). DAG and fatty acyl-CoA are then used to form TG, 
catalyzed by acyl-CoA:1,2-diacylglycerol O-acyltransferase (see below) (reviewed 
by [CHEN et al., 2000; FARESE, JR. et al., 2000; GRIGOR et al., 1982; LEHNER 
et al., 1996; YEN et al., 2008]). The rate of TG synthesis is dependent on the 
availability of the substrates, i.e., glycerol-3-phosphate precursors and long-chain 
FA, and the activities of the enzymes involved [MAYOREK et al., 1985]. 
 
2.2.2.3  Regulation of TG synthesis 
 
The complex regulation of TG formation and hydrolysis involves transcriptional and 
post-transcriptional controls that respond to food-derived metabolites and specific 
hormones as well as exercise-mediated energy expenditure [COLEMAN et al., 
2000].  
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Crucial lipogenic transcription factors, such as 
sterol regulatory-element-binding protein-1c 
(SREBP-1c), peroxisome proliferator-activated 
receptor γ (PPARγ), liver X receptors (LXR) and 
the nutritional and hormonal regulators insulin, 
carbohydrate, and FA (e.g. poly-unsaturated FA 
(PUFAs)), play an important role in the 
regulation. The regulation can differ greatly in 
various tissues, e.g., TG synthesis in liver and  
Figure 2.13: Regulation of lipogenic 
and TG genes by SREBP, LXR, 
PUFAs, glucose, and insulin. 
[Source: [COLEMAN et al., 2004]] 
adipose tissues is unlike that in milk producing breast epithelial cells [COLEMAN et 
al., 2004].  
 
2.3 Enzymes of triglyceride synthesis 
 
The sequential re-esterification of 2-MAG to TG in enterocytes has been suggested 
to be catalyzed by a ‘TG synthetase complex’. This complex contains acyl-
CoA:monoglyceride acyltransferase (MGAT), acyl-CoA:diacylglycerol acyl 
transferase (DGAT) and a FA activating enzyme for the initial enzymatic step, acyl-
CoA synthetase (including acyl-CoA ligase and acyl-CoA acyltransferase) 
[LEHNER et al., 1995; RAO et al., 1966]. 
 
2.3.1 Diacylglycerol O-acyltransferase 1 
 
Acyl-CoA:1, 2-diacylglycerol O-acyltransferase 1 (DGAT1; EC 2.3.1.20), an integral 
membrane protein, is the key enzyme in TG synthesis. It contains 6-12 
transmembrane domains, which form a homotetramer [CASES et al., 1998; 
CHENG et al., 2001; LEHNER et al., 1996]. DGAT1 catalyzes the final and rate-
limiting step [MAYOREK et al., 1989] in the glycerol phosphate and mono-
acylglycerol pathway, in which sn-1,2-diacylglycerol (DAG) is covalently bound to 
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long chain FA CoA (see Figure 2.14 and Figure 2.15) [CHEN et al., 2000; 
COLEMAN et al., 2004; FARESE, JR. et al., 2000; YEN et al., 2008]. 
 
Figure 2.14: Triglyceride synthesis in the diacyl-
glycerol acyltransferase reaction. 
GPAT, glycerol-phosphate acyltransferase; AGPAT, 
acyl-glycerol-phosphate acyltransferase; PAP, 
phosphatidic acid phosphohydrolase; MGAT, acyl 
CoA: monoacylglycerol acyltransferase. 
[Source: adapted from [YEN et al., 2008]] 
 
 
Figure 2.15: Formation of an ester 
linkage between fatty acyl CoA and 
1,2-diacylglycerol to form TG. 
This reaction is catalyzed by DGAT 
at the surface of the endoplasmic 
reticulum (ER). 
[Source: [YEN et al., 2008]] 
 
DGAT1 activity (first reported by [WEISS et al., 1960] has been localized 
predominantly to the cytosolic (‘overt’ activity) and luminal (‘latent’ activity) surface 
of the endoplasmic reticulum (ER) membrane in rat liver cells [ABO-HASHEMA et 
al., 1999; FARESE, JR. et al., 2000; OWEN et al., 1997; WATERMAN et al., 2002]. 
One model suggests that the overt DGAT activity catalyzes the synthesis of TG 
which are then incorporated into cytosolic lipid droplets (storage form), whereas the 
latent DGAT activity catalyzes the synthesis of TG-rich LP (e.g. nascent VLDL) for 
secretion. This model proposes that DAG freely crosses the ER membrane and 
that FA CoA moieties are transported by a carnitine acyltransferase through the ER 
membrane into the lumen (see Figure 2.16 and Figure 2.17) [FARESE, JR. et al., 
2000; WATERMAN et al., 2002; YEN et al., 2008].  
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Figure 2.16: Metabolic scheme illustrating the 
suggested functions of the overt (cytosolic) and 
latent (luminal) DGAT enzymes in the ER by rat 
liver. 
[Source: [WATERMAN et al., 2002]] 
 
 
Figure 2.17: The role of DGAT enzymes in the 
synthesis and secretion of TG in the ER (a 
hypothetical model). 
[Source: [YEN et al., 2008]] 
 
Because of its essential role in TG synthesis, DGAT1 is involved in intestinal fat 
absorption, regulation of plasma TG concentration and lipoprotein (LP) assembly, 
as well as fat storage in adipose tissue, energy metabolism in muscle and lactation 
(reviewed by [CASES et al., 1998]). Although DGAT1 was originally identified as a 
TG synthesis enzyme, recent findings indicate that DGAT1 also catalyzes the 
formation of DAG, monoester and diester waxes, and retinyl esters (from retinol) in 
vitro [KALSCHEUER et al., 2003; LUNG et al., 2006; YEN et al., 2005]. 
 
2.3.1.1 Identification and cloning of a DGAT gene 
 
In 1998, a mammalian cDNA encoding a DGAT (now known as DGAT1), which 
shares homology with sequences in the acyl CoA:cholesterol acyltransferase 
(ACAT; EC 2.3.1.26) C terminus, was identified and cloned by Cases et al.. In 
humans, the DGAT1 gene is located on chromosome 8 and encodes about 500 AA 
(calculated molecular mass (MM) ~55kDa) [CASES et al., 1998]. DGAT mRNA is 
widely expressed in mouse and human tissues, with the highest activity in tissues 
typically associated with TG synthesis. Particularly high levels occur in small 
intestine, liver, and skeletal muscle, but high DGAT mRNA expressions have also 
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been found in adipose tissue and mammary glands [CASES et al., 1998; FARESE, 
JR. et al., 2000]. In fungi and plants, DGAT is associated with the membrane and 
oil body fractions, mainly in oil seeds, where it contributes to the formation of 
storage lipids [LUNG et al., 2006]. 
 
2.3.1.2 Regulation of DGAT enzymes 
 
In cultured hepatocytes (HepG2 hepatoma cells), DGAT1 mRNA levels are 
regulated by the MEK/ERK signaling pathway, showing a 2-fold increase due to 
inhibition of this signaling pathway (reviewed by [YEN et al., 2008]). DGAT1 gene 
expression in adipocytes is subject to transcriptional and posttranscriptional 
regulation, which was shown to be the principle mechanism. This is indicated by a 
marked increase in DGAT1 activity (~100-fold), DGAT1 protein (~90-fold) and 
mRNA level (~8-fold) in mature mouse 3T3-L1 adipocytes (a model for mammalian 
adipocytes) compared with preadipocytes [CASES et al., 1998; YU et al., 2002]. 
These findings indicate an upregulation of DGAT enzymes during adipogenesis 
and suggest the involvement of CCAAT (cytidine-cytidine-adenosine-adenosine-
thymidine)-enhancer-binding protein α (C/EBPα) or PPARγ. C/EBPα and PPARγ 
are transcription factors that are involved in gene expression in adipogenesis 
(reviewed by [YEN et al., 2008]). Glucose also controls DGAT mRNA expression in 
3T3-L1 adipocytes, showing an increased expression in response to glucose 
(25mM) [HIRATA et al., 2006; MEEGALLA et al., 2002]. Moreover, glucose 
administration also induces tumor necrosis factor α (TNF-α; a cytokine implicated 
in obesity-related insulin resistance) mRNA expression in these cells [HIRATA et 
al., 2006]. This suggests an important role of DGAT in the control of cytokine 
expression in visceral adipocytes. Therefore, an inhibition of DGAT1 leads to an 
inhibition of TNF-α gene expression [HIRATA et al., 2006]. Otherwise, when an 
improperly high level of mRNA is produced, (e.g. in Ad-hDGAT1-transduced cells), 
the rise in protein expression is curbed at the posttranscriptional level, in order to 
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maintain intracellular TG homeostasis. Consistent with these findings, it is also 
clear that the steady-state level of DGAT1 protein primarily determines DGAT1 
activity, and that this protein level is crucially regulated by posttranscriptional 
mechanisms [YU et al., 2002]. Any changes, e.g., over expression of DGAT genes, 
actually seem to be linked to lipotoxicity, as demonstrated by an increased TG 
accumulation [CHEN et al., 2002d; MILLAR et al., 2006] and intramyocellular lipid 
increase [ROORDA et al., 2005], respectively, in insulin-sensitive tissues other 
than adipocytes (liver, skeletal muscle, and intestine) [CASASCHI et al., 2005; 
CHEN et al., 2002d; UNGER, 2002; YU et al., 2002]. These findings may point to a 
potential role of DGAT1 enzyme in the development of obesity, insulin resistance 
and T2DM [CASASCHI et al., 2005; YU et al., 2002]. Evidence for this association 
between insulin resistance and TG accumulation comes from insulin-resistant 
animal models [CASASCHI et al., 2005]. 
 
2.3.1.3 DGAT1 deficiency in mice 
 
DGAT1-deficient (DGAT-/-) mice have been generated to investigate the biological 
functions of the DGAT1 gene in energy and glucose metabolism, and in particular 
in TG synthesis [CHEN, 2006; SMITH et al., 2000]. DGAT-/- mice are viable and 
fertile, but their white adipose tissue (WAT), liver and muscle TG content are lower 
than in wild-type (WT) (DGAT+/+) mice [BUHMAN et al., 2002; SMITH et al., 2000].  
Also, DGAT-/- mice tend to have lower DAG levels in these tissues (liver, skeletal 
muscle) [CHEN, 2006]. Their adipocytes are protected from high-fat diet-induced 
hypertrophy compared to WT mice, whose fat cell size doubles in this situation 
[CHEN et al., 2002b]. DGAT1 deficiency also alters the FA composition of TG in 
adipose tissue and muscle, resulting in a relative increase in saturated FAs (C16:0 
and C18:0) and a relative decrease in monounsaturated FAs (C16:1 and C18:1) 
[CHEN et al., 2002b]. Although this mechanism remains incompletely understood, 
it may reflect a kind of preference for unsaturated FAs in the DGAT1-mediated TG 
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synthesis. DGAT-/- females have a complete absence of lactation because DGAT 
deficiency also alters TG metabolism in the mammary glands, characterized by a 
lack in lipid droplets in epithelial cells [SMITH et al., 2000]. DGAT-/- mice show an 
increased sensitivity to insulin (for insulin, see Chap. 2.1.2.2) and leptin (for leptin, 
see Chap. 2.1.2.1). This enhanced insulin sensitivity can be ascribed to the 
increased glucose transport in skeletal muscle and adipose tissue [CHEN et al., 
2002b; CHEN et al., 2004]. In addition, key molecules in the insulin signaling 
pathway, e.g., PKB (or Akt), PKC-λ and phosphatidylinositol-3 kinase, are 
increased. Otherwise, there is a decrease in serine phosphorylation of IR-
substrate-1, a molecule involved in insulin resistance. These findings were 
observed in chow-fed DGAT1+/+  mice transplanted with DGAT1-/- WAT [CHEN et 
al., 2004]. Moreover, the increase in insulin sensitivity is associated with a reduced 
TG content in liver and skeletal muscle as well as a decreased adipocyte size 
[CHEN et al., 2002b]. It has also been demonstrated that the effects of DGAT1 
deficiency on glucose and energy metabolism only occur in the presence of leptin, 
as shown in leptin-resistant Agouti yellow (Ay/a) mice and leptin-deficient (ob/ob) 
mice, respectively, two genetic models of insulin resistance and obesity [CHEN et 
al., 2002a]. But surprisingly, there is no change of the effect of ICV leptin infusion 
on food intake in energy balance in DGAT-/- mice, suggesting an enhanced leptin 
action directly in peripheral tissues and not in the hypothalamus [CHEN et al., 
2002a]. DGAT-/- mice are also resistant to high-fat diet-induced obesity (DIO) 
(see Figure 2.18), accompanied by an increase in total 
EE, i.e., a ~20% higher metabolic rate compared with WT 
mice [BUHMAN et al., 2002; SMITH et al., 2000]. These 
mice also tend to have improved glucose disposal after a 
glucose load [SMITH et al., 2000]. Increased physical 
activity contributes to the elevated EE in DGAT 
deficiency, but alternative mechanisms mediating the 
increased EE are subjects of current studies 
 
Figure 2.18: Phenotype of 
DGAT1 deficiency in mice. 
[Source:[YEN et al., 2008]] 
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 (e.g. increased thermogenesis or β-oxidation of FA) [CHEN et al., 2000; SMITH et 
al., 2000]. In DGAT1-/- mice, brown adipose tissue (BAT) uncoupling protein 1 
(UCP1) expression as well as WAT UCP3, PPARα, and acyl-CoA oxidase 
expression (genes involved in FAO) are increased, whereas the expression of 
PPARγ and FA synthase (genes involved in adipogenesis) are decreased. The 
leptin mRNA expression is also decreased by ~50 %. The reduced leptin levels are 
consistent with the observation that DGAT-/- mice have increased leptin sensitivity, 
which primarily affects EE without a comparable effect on FI [CHEN et al., 2002b]. 
To show the importance of WAT in endocrine functions, Chen et al. transplanted 
WAT from DGAT-/- mice into DGAT+/+ recipient mice. As a result, obesity 
resistance, enhanced glucose disposal and increased activation of insulin signaling 
pathway were conferred to DGAT+/+ recipient mice [CHEN et al., 2003; CHEN et 
al., 2004]. Furthermore, DGAT1 deficiency in adipocytes seems to increase the 
expression of adiponectin, an adipose tissue hormone that enhances FAO and 
insulin sensitivity and, hence, increases resistance to obesity [CHEN et al., 2003]. 
These findings demonstrate that the altered endocrine function of the DGAT-
deficient WAT has a beneficial effect on systemic energy turnover and glucose 
metabolism. 
Although DGAT-/- mice are unable to express a functional DGAT enzyme, they are 
still capable of synthesizing TG, resulting in similar fasting serum TG levels when 
compared to WT mice [CHEN et al., 2000; SMITH et al., 2000]. Furthermore, 
DGAT1 is not essential for dietary TG absorption or for CM synthesis. There is only 
a reduction in postabsorptive chylomicronemia in the cytoplasm of enterocytes, 
suggesting a reduced rate of TG absorption after a lipid load [BUHMAN et al., 
2002]. All these findings indicate that alternative mechanisms must exist, and there 
are in fact at least two other enzymes, a second DGAT (DGAT2) and diacylglycerol 
transacylase, that contribute to TG synthesis in liver and intestine, and which may 
compensate for the absence of DGAT1 [BUHMAN et al., 2002].  
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2.3.2 DGAT2 – an isoform of DGAT1 
 
The DGAT2 enzyme is an integral membrane protein in the ER bilayer (like 
DGAT1) which contains two transmembrane domains. Both, the N and C termini 
are exposed to the cytosol, i.e., most of the protein (~87%) faces the cytosol. This 
suggests that DGAT2 has its active site on the cytoplasmic side of the ER 
membrane and thus contributes only to the overt DGAT activity (cytosolic lipid 
droplet synthesis; see above Figure 2.16 and Figure 2.17) Furthermore, DGAT2 
may be important in the initial TG synthesis [STONE et al., 2006].  
The human DGAT2 gene is located on the chromosome 11 and encodes a protein 
of 350-400 AA (calculated MM ~40 to 44 kDa) [YEN et al., 2008]. In human 
tissues, two mRNA species (~1.8 and ~2.4 kilobases) are identified, and the 
highest DGAT2 expression levels are observed in liver and WAT. Lower levels are 
found in the mammary gland, testis and in the peripheral blood leukocytes. 
Surprisingly, DGAT2 expression is absent in the small intestine of humans, 
however, gene expression in mouse small intestine exists [CASES et al., 2001]. 
Because of its high expression in liver, DGAT2 is more likely to play an important 
role in the LP VLDL assembly of the de novo synthesized of FA from surplus of 
carbohydrates [MEEGALLA et al., 2002]. 
DGAT2-deficient mice were generated by Stone et al. to 
investigate the role of DGAT2 in TG synthesis and energy 
homeostasis [STONE et al., 2004]. In comparison to 
DAGT1-/-, DGAT2-/- mice are smaller, and they die shortly 
after birth, because inactivation of DGAT2 leads to lethal 
abnormalities in energy homeostasis and skin functions 
(defective skin-barrier function, e.g. transepidermal water 
loss, and necrotic tail (arrow); see Figure 2.19). 
 
Figure 2.19: Phenotype of 
DGAT2 deficiency in mice. 
[Source: [STONE et al., 
2004]] 
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2.3.3 Inhibition of DGAT  
 
Inhibition of DGAT2 expression in liver and adipose tissue of adult DIO and ob/ob 
mice has been achieved by using an optimized antisense oligonucleotide (ASO). 
This DGAT2 ASO treatment caused a noticeable reduction in hepatic TG content 
[CHOI et al., 2007; YU et al., 2005] and secretion rate; it also improved hepatic 
steatosis, possibly due to activation of hepatic FAO and inhibition of hepatic 
lipogenesis. There are also several naturally occurring compounds from fungal and  
plant extracts, e.g. xanthohumol (a natural product 
from Humulus lupulus) [TABATA et al., 1997], 
amidepsine A (produced by Humicola sp.) [TOMODA 
et al., 1995], roselipins (produced by Gliocladium 
roseum) (see Figure 2.20) [TOMODA et al., 1999], 
that can inhibit DGAT activity. Many other plant-
derived inhibitors, e.g., taxifolin, polyacetylens, and 
tanshinone have been discovered by different groups 
(reviewed by [TOMODA et al., 2007]). Inhibition of 
DGAT by long-chain 2-bromooctanoate in cultured 
rat hepatocytes (first reported by [MAYOREK et al., 
1985]) leads to an inhibition in TG synthesis in a 
dose-dependent manner, accompanied by 
accumulation of DAG but not by restriction of general
 
Figure 2.20: Chemical structure 
of Xanthohumol, Amidepsine A 
and Roselipin. 
[Source: [SHI et al., 2004; 
TOMODA et al., 1999]] 
neutral lipid synthesis. Betulinic acid (3β-hydroxy-lup 
-20(29)-en-28-oic acid (see Figure 2.21), a naturally 
pentacyclic triterpene) from Alnus hirsuta [CHUNG et 
al., 2006] and eicosapentaenoic acid (C20:5) are 
also reported to be potent inhibitors of DGAT in rat 
liver microsomes [BERGE et al., 1999; RUSTAN et 
al., 1988]. Studies on DGAT1-/- mice suggest that  
 
Figure 2.21: Chemical structure 
of Betulinic acid. 
[Source: [KUMAR et al., 2008]] 
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pharmacological inhibition of DGAT1 may be a possible strategy for the treatment 
of obesity  and T2DM, but further investigations need to address the selectivity 
toward the DGAT isoenzymes [CHEN et al., 2000; TOMODA et al., 2007]. 
 
This thesis focuses on a pharmacological inhibition of DGAT1, in particular on its 
possible effect on food intake and metabolism.  
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3 MATERIALS AND METHODS 
 
3.1 Animals and housing 
 
Ten male Sprague-Dawley (SD) rats (240-270 g BW) at the time of arrival) from 
Charles River (Sulzfeld, Germany) were caged individually in custom-made 
Macrolon plastic cages (44 x 20 x 36 cm) with stainless steel grid floors in a 
temperature controlled test room (22 ± 2°C) with a 12:12-h light-dark cycle (lights 
off at 10:00). All cages were fitted with appropriately sized plastic “sleeping tubes” 
where animals could rest. The animals were adapted to housing conditions for at 
least one week before gastric and jugular vein catheter surgery. Beginning two 
days before surgery, the animals were adapted to a 16 h deprivation 8h feeding 
schedule (food access from 10:00 to 18:00, i.e. during the first 8 h of the dark 
phase). At 18:00 food was taken out of the cage and the food intake (FI) of each 
animal was recorded daily. The BW and wellbeing of the animals were checked 
daily at the same time. Routine checks included observing that the animals were 
normally alert and active, had food and water and clean bedding. All procedures 
were approved by the Canton of Zurich Veterinary Office. 
 
3.2 Surgery 
 
After six days adaption to the housing conditions all animals were equipped with 
jugular vein catheters and with gastric catheters (see Chapter 3.2.4). The BW on 
the day of surgery (19.03.2008) was 270-300 g. After surgery animals were 
allowed to recover for 21 days before the first experiment (see Chapter 3.6.1). 
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3.2.1 Chronic Jugular vein (JV) catheter 
3.2.1.1 Introduction 
 
The method and volume of blood to be collected from laboratory animals depends 
on the animal species, frequency of collection, and experimental needs. Blood can 
be sampled for example by puncture of the ophthalmic venous plexus, puncture of 
the heart, cutting the tail or even by decapitation. With all these methods the 
animal has to be either anesthetized or handled and restrained. All these 
techniques may therefore induce stress, i.e., endocrine changes such as an 
elevation of circulating catecholamine and corticosteroid levels, which may change 
the target variable.  To avoid these effects it is preferable to take blood samples 
from less disturbed animals through a previously implanted catheter. We therefore 
decided to equip all our rats with a jugular vein catheter according to a cannulation 
procedure described by Steffens [STEFFENS, 1969], with some modifications 
[FERRARI et al., 2005; REMIE et al., 1990]. 
 
3.2.1.2 Preparation of materials for cannulation 
 
The jugular vein catheter consisted of silastic tubing (ID: 0.508mm, OD: 0.939 mm, 
length 10.5 cm; ID: 1.47 mm, OD: 2.159 mm, length 1.3 cm; Gore W.L., Newark, 
DE, USA), a 20 gauge (G) Vacutainer cannula as adapter (Becton-Dickinson, 
Basel, Switzerland) and a polypropylene surgical mesh (Bard, New Jersey, NY, 
USA) to improve adhesion to skin and fascia.  
For the adapter the yellow tip of the cannula was broken off with a pincer and the 
end of the cannula was polished to obtain a smooth and round surface. The next 
step was to bend the cannula with a round pincer in an L-shaped form with an 
angle of more than 100°. The plastic Vacutainer hub was broken off in the same 
way as the tip and the end was polished, too. Afterwards the adapter was fit into 
one end of the 10.5 cm tubing (ID: 0.508 mm, OD: 0.939 mm). To be able to slide 
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the silicon tube over the adapter, the end of the tube was soaked in ether for some 
seconds to make it more stretchable. After the tube-adapter-construct was dried 
and shrunk again, a 1.3 cm piece of thicker tubing (ID: 1.47 mm, OD: 2.159 mm) 
which had been placed in ether before was fit over this end of the cannula as a 
reinforcement. After complete drying the adapter-tubing-construct was checked for 
possible leakage. A 1 ml syringe (Omnifix®, B.Braun, Melsungen, Germany) with a 
rounded 20 G-cannula was filled with ethanol and connected to the catheter with a 
short piece of PE-tubing (Tube PE-60; 0.76x1.22 mm; Smiths Medical, London, 
England). The system was considered tight when no ethanol leaked through the 
adapter tubing connection part. In a next step the catheter was fixed to a piece of 
non absorbable surgical mesh (2.2x6 cm) to facilitate adhesion to the skin and 
fascia. The mesh was folded into a square (2.2x3 cm) of two layers. The adapter 
piece of the catheter was led through a hole in the top fold of the mesh so that the 
catheter was positioned between the two layers of mesh. The adapter was then 
fixed to the mesh with cross stitches of a 3/0 silk thread (B.Braun, Melsungen, 
Germany) and all edges were rounded. Finally, the tightness of the catheter was 
checked again (see above).  
With a rounded 20 G-needle two holes were made 0.5 mm distant to the end of the 
silastic tubing to ensure that the catheter would not attach to the wall of the atrium 
when aspirating blood. For the fixation of the catheter in the vein a small band of 
silicon was applied around the tubing, 3.8 mm away from the distal end. The liquid 
silicon (Silicone Adhesive, Cook Veterinary Products, Queensland, Australia) was 
applied using a 1 ml syringe and a polished 18 G-cannula in order to achieve a 
uniform circle. For this procedure the catheter was fixed on a small rack with the 
end of the tubing hanging down loosely. Finally the catheter was dried for one hour 
at 50°C. Before catheter implantation all catheters were gas sterilized with 
ethylene-oxid. 
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3.2.2 Chronic intragastric (IG) catheter 
 
3.2.2.1 Preparation of materials for cannulation 
 
The gastric catheter was assembled from silastic tubing (ID: 0.762 mm, OD: 1.651 
mm, Gore W.L., Newark, DE, USA length 17 cm), with one end reinforced with 
another piece of silastic tubing (ID: 1.47 mm, OD: 1.95 mm, Gore W.L., Newark, 
DE, USA, length 1.3 cm), a 20 G Vacutainer cannula as adapter (Becton-
Dickinson, Basel, Switzerland), and polypropylene surgical mesh (Bard, New 
Jersey, NY, USA). The adapter was made in a similar way as for the jugular vein 
catheter described above, except that the cannula was bend into a U-form (see 
figure) instead of an L-form and that three (instead of one) silicon bands were 
applied in different positions in order to help keep the catheter in place. The three 
silicon bands around the tubing were applied at 7 mm (small circle), 8 mm (medium 
size circle) and 4 cm (medium size circle) from the distal end. Also, we did not 
puncture holes into the end of the catheter because no fluids were aspirated.  
 
3.2.3 Combined JV and IG catheter 
 
A gastric catheter and a jugular vein catheter were assembled as described above. 
Both adapter-tubing constructs were fixed between two layers of non absorbable 
surgical mesh (2.2x3 cm). The adapter pieces protruded from the mesh in one line 
with a 7-10 mm distance between them. The adapter of the IG catheter was placed 
cranial of the IV catheter adapter and its tubing was directed caudally, whereas the 
tubing of the JV catheter was directed cranially. 
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3.2.4 JV and IG cannulation  
3.2.4.1 Preoperative evaluation and preparation 
 
Prior to surgery, each animal was examined for the presence of any clinical signs 
that could affect its ability to survive the anesthetic and surgical protocol. On the 
eve of the surgery food was removed from the first five rats (2-3 standard chow or 
high fat pellets were left in the cage overnight). The rats had ad lib access to tap 
water until one hour before surgery. Three hours prior to anesthesia all animals 
received a subcutaneous (SC) injection of 200 µl of the broad-spectrum antibiotics 
Borgal 24% (Intervet, Veterinaria AG, Zurich, Switzerland), diluted 1:6 with saline 
(NaCl 0.9%, B.Braun Medical AG, Sempach, Switzerland) for infection prophylaxis 
and food was removed from the remaining animals. Fifteen to 30 min prior to 
anesthesia the animals were pretreated with 100 µl/100g atropine SC 
[0.05mg/kg/day] (Sintetica S.A, Mendrisio, Switzerland), diluted with saline 1:10. 
Inhalation anesthesia was induced in an induction chamber (animals were adapted 
to the chamber) with 4-5 % isoflurane (Minrad Inc. USA, Provet AG) in oxygen 
1000 ml/min (Pan Gas Dübendorf, Switzerland). When surgical tolerance was 
reached, anesthesia was maintained with 1-3 % isoflurane, oxygen and 
dinitrogenoxide, 300 ml/min each. Throughout surgery the depth of anesthesia was 
checked frequently by testing of reflexes (e.g., corneal reflex) and lack of response 
to stimuli (such as pinching a toe).  The depth and frequency of breathing was also 
monitored. 
The sites of surgery (the back from the lumbar region over the whole neck; the 
abdomen from the pubic bones to the sternum; the right ventral side of the neck 
from the right clavicle to the mandible) were shaved and disinfected with Braunol 
(Braunol®2000, B.Braun Medical AG, Emmenbrücke, Switzerland). The cornea of 
the animals was protected from drying out with an eye ointment (Vitamin A 15000 
IE/g, Bausch&Lomb, Steinhausen, Switzerland), and the animals were kept on 
heating pads (39°C) throughout the surgery to prevent hypothermia. All 
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instruments and catheters were sterilized (autoclave and diethylene dioxid, 
respectively) and all surfaces in the surgery room were disinfected using 70 % 
ethanol.  
 
3.2.4.2 Surgical Procedure 
 
A 2.5 cm long median dorsal cutaneous incision was made just caudal to the 
interscapular area, and the positions for the JV and IG cannula access ports were 
marked rostral to the incision between the scapulae (Figure 3.1). Starting from the 
incision, straight hemostats were pushed in cranial direction through the 
subcutaneous connective tissue to the marked ports to generate the space for the 
double layer of polypropylene surgical mesh. The skin was then pierced with a bent 
18 G needle for the two cannula ports (Figure 3.2).  
Figure 3.1: Cutaneous median dorsal incision 
caudal to the interscapular area. 
Marking of the JV and IG cannula position 
between the scapulae where the cannula ports 
were exteriorized. 
 
Figure 3.2: Perforation of the skin with a bent 
18G needle to generate the catheter ports. 
 
Next, a 2 cm ventral cervical skin incision was made right of the midline with its 
caudal end at the level of the clavicle (Figure 3.7). Small artery forceps were then 
pushed under the skin to generate a tunnel from the ventral cervical incision to the 
median dorsal cutaneous incision. The distal end of the JV cannula was then 
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grasped with forceps and led subcutaneously from the dorsal incision to the right 
clavicle by pulling the forceps back (Figure 3.3). 
Figure 3.3: Subcutaneous tunneling of the JV 
cannula. 
Figure 3.4: Subcutaneous tunneling of the IG 
cannula. 
 
The folded mesh with the adapters was placed in the correct position under the 
skin so that the adapters of both the JV and IG cannulas protruded out of the 
puncture wounds. Each adapter was then connected via PE-tubing (0.76x1.22 mm) 
to a syringe containing saline (Figure 3.5). Afterwards, a 4 cm ventral midline skin 
incision was made using a scalpel from the level of the xiphoid cartilage with the 
caudal end at the level of the pubic bones. The IG cannula was then led through a 
lateral subcutaneous tunnel from the median dorsal incision to the abdominal skin 
incision on the left side of the rat (Figure 3.4). Subsequently, the dorsal incision 
was closed with a 3/0 absorbable Vicryl thread by surgeon’s knots (4-5) (Figure 
3.6). 
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Figure 3.5: Connection of the IG and JV port 
with PE-tubing. 
Figure 3.6: Suture of the dorsal incision. 
 
 
The rat was then turned into a supine position with its head towards the surgeon 
and the 2 cm ventral cervical skin incision (see above) was draped with sterile 
gauze (5x5 cm; IVF, Neuhausen, Switzerland). Blunt forceps were used to push 
aside connective and adipose tissue to expose the division of the external jugular 
vein into the maxillary vein, and the linguofacial vein (Figure 3.8). At this point the 
largest vessel was chosen for cannulation and mobilized over a distance of about 5 
mm. A loose ligature (3/0 silk thread) was placed caudally on the external jugular 
vein, and the maxillary vein as well as the linguofacial vein were ligated 3mm 
rostral from the bifurcation (3/0 silk thread) (B.Braun, Melsungen, Germany).  
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Figure 3.7: Place of incision.  
Imaginary lines to determine the exact 
location of the jugular vein bifurcation. 
(A) Incision, (B-C) line between the left arm 
pit and the right ear, (D-E) line between the 
right arm pit and the chin. [Source: adapted 
from [REMIE, 2000]]. 
 
Figure 3.8: Dissection of the external jugular vein. 
View of the ventral surface of the rat’s neck with the 
external jugular vein (ejv), the linguofacial vein (lfv), 
and the maxillary vein (mv). 
 
 
 
With a 20 G needle the wall of the linguofacial vein was pierced 2 mm rostral to the 
bifurcation (Figure 3.9). The vessel was dilated by sharp-pointed jeweller’s forceps 
to be able to insert the distal end of the sterile jugular vein catheter between the 
legs of the forceps (Figure 3.10). Prior to its insertion the catheter was flushed and 
filled with saline. The catheter was pushed gently into the vessel until the silicon 
band reached the point of perforation (Figure 3.11). Previous studies indicated that 
the end of the cannula was then located at the level of the right atrium. The 
catheter was secured in place by two ligatures. First the loose caudal ligature 
around the catheterized vessel was tied and the rostal ligature was used to anchor 
the cannula to the vessel. The two ligatures were cross tied with each other to 
ensure that the cannula could not move. Subsequently, the catheter was checked 
for patency by aspirating some blood and flushing with saline. The cervical skin 
incision was closed in two layers, using a continuous subcutaneous suture for the 
muscular layer and single knot skin suture with 5/0 and 3/0 absorbable Vicryl 
(Ethicon® 3/0, Johnson &Johnson, Spreitenbach, Switzerland).  
 
 
Head 
ejv 
mv 
lfv 
C E 
A 
B
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The jugular vein catheter was finally filled with 100 µl heparinized 
polyvinylpyrrolidone (PVP; preparation see Chap.3.3.2) and the outer part of the 
cannula (3-4 cm PE-60 tubing (0.76x1.22 mm) was sealed with a stainless steel 
pin (“stopper”), which was made out of an obturated, blunt 20 G needle.  
 
Figure 3.9: Piercing of the maxillary wall 2 mm 
rostral from the bifurcation with a 20 G needle. 
Figure 3.10: Dilation of the vessel with a sharp-
pointed jeweller's forceps. 
 
 
 
Figure 3.11: Insertion of the JV catheter into 
the vessel. 
 
Figure 3.12: Fixation of the JV catheter to the 
vein. 
 
After the JV catheter implantation the abdominal cavity was opened in the linea 
alba with a sharp-blunt pair of scissors. A hole was made through the abdominal 
muscle using a 18 G needle and the distal end of the IG cannula was led through it 
caudal ligature 
rostral ligature 
                                                                                                          Materials and methods 
 
 
 
  47 
 
until the third silicon circle (most proximal to the adapter part) was inside the 
abdominal cavity. The stomach was then partially exteriorized and held in place 
with cotton swabs (Novamed, St.Gallen, Switzerland) dampened with warm saline. 
A 3 mm diameter purse-string suture with a 4/0 non-absorbable silk (Johnson & 
Johnson, Spreitenbach, Switzerland), was loosely placed on the greater curvature 
(Figure 3.13). The center of the purse-string was punctured with an 18 G needle 
and the catheter was inserted until the first silicon band (small one, most distal) 
was inside the stomach and the second silicon band was outside the stomach wall 
(Figure 3.14). 
 
 
Figure 3.13: Placing a 3mm diameter purse-
string suture on the greater curvature of the 
gastric corpus. 
 
Figure 3.14: Insertion of the IG cannula into the 
stomach. 
 
The purse-string was then tightened around the catheter and a 3/0 silk thread was 
placed rostal to the first silicon band and connected to the purse-string suture 
(Figure 3.15). In addition, the cannula was fixed to the abdominal wall using the 
third silicon band and non-absorbable 4/0 silk. The abdominal muscle layer was 
closed using an interrupted suture technique with 3/0 absorbable Vicryl, and the 
skin incision was then closed with an interrupted 5/0 absorbable Vicryl suture. 
Subsequently, the catheter was filled with sterile saline and the tubing was sealed 
with a stopper (Figure 3.16). 
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Figure 3.15: Fixation of the IG cannula on the 
stomach wall. 
 
Figure 3.16: JV and IG catheter access ports. 
 
3.2.4.3 Post-operative care 
 
During immediate recovery from the anesthesia, all animals were closely monitored 
and single bedded in clean recovery cages under an infrared lamp to assure 
thermoneutrality and to prevent heat loss. One-two hours after surgery the animals 
received a SC injection of 100 µl/100 g of the analgesic carprofen (Rimadyl®, Pfizer 
AG, Zurich, Switzerland), diluted 1:10 with saline [5 mg/kg/day]. Normal husbandry 
practices were resumed after the animals had recovered from anesthesia and 
regained mobility. On the following day all rats received SC antibiotics (Borgal®, 
see above) and analgesics (Rimadyl®, see above), and two days after surgery only 
analgesics. During the first week after surgery the JV catheters were flushed 
regularly (see Chap.3.3.3). All sutures as well as the animals’ wellbeing and BW 
(illustrated in Figure 3.17) were controlled daily, and all animals were allowed to 
recover for at least ten days before experiments began. 
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Figure 3.17: Body weight gain for rats after jugular vein and gastric cannulation fed ad libitum (i) 
HFD (ii) Standard Chow 
 
 
3.3 JV and IG catheter maintenance 
 
3.3.1 Preparation of materials for catheter maintenance 
 
For catheter maintenance the following materials were needed: PE-tubing (PE-60, 
0.76x1.22 mm, ~20 pieces, length: ~25 cm), syringe assemblies (1 and 10ml 
syringe attached to a 20G blunted cannula), custom-made “connectors” (made out 
of a 20 G Vacutainer cannula from which the yellow cap and the tip were broken off 
and the ends were polished), heparinized polyvinylpyrrolidone (PVP) as a catheter 
“lock” solution (see Chapter 3.3.2), sterile saline and 70% ethanol.  
All PE-tubing was filled with 70% ethanol, and stoppers and connectors were left in 
ethanol for more than 20 minutes. The blunted 20 G cannula was autoclaved (1 
bar, 50 minutes) before use. 
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3.3.2 Preparation of the catheter lock solution (heparinized PVP) 
 
As mentioned above, heparinized polyvinylpyrrolidone (PVP-10; Sigma, St. Louis, 
USA) was used as a catheter lock solution for the JV catheter. Twenty-one g PVP 
(powder) was filled in a 50 ml Falcon tube and 12.0 ml 0.9 % NaCl was added. The 
tube was closed immediately and shaken vigorously for some minutes. Under light 
heating (<50°C) in a water bath and with frequent shaking the PVP was dissolved 
in saline until a homogeneous viscous solution was generated. This solution was 
aliquoted into three glass vials, loosely closed with a lid and autoclaved (1 bar, 50 
min). The resulting highly viscous solution was then stored in the refrigaretor at 
4°C. Before use the PVP solution was warmed (<37°C) and 1 ml Heparin (25000 
IU/ml) (Heparin-Na (50000 IU/5ml), B.Braun) was added.  
 
3.3.3 Flushing regime to maintain catheter patency 
 
After successful intravenous catheter implantation, the amount of time that it 
remains patent sets limits to its use. Therefore, a maintenance program of regular 
flushing was necessary to allow for repeated blood sampling and infusions over 
longer periods of time. During the first week after surgery, JV and IG catheters 
were flushed daily, during the second week every second day and thereafter every 
third day. Before flushing the catheters, the PE-tubings, which were filled with 70 % 
ethanol before (see above) were rinsed with sterile saline. One ml syringes were 
then filled with sterile saline and attached to the 20 G blunted needles. Afterwards 
the syringe assemblies were connected to the PE tubing with a connector on one 
end, and each tube was rinsed thoroughly to remove all air inside. The PVP was 
prepared as described above and filled in 1ml syringes which were then also 
connected to PE-tubing. The JV catheter flushing procedure was as follows. First, 
the pin from the catheter was removed and put in 70 % ethanol. The syringe-tubing 
assembly was then connected to the access port of the catheter via the connector 
piece and the lock solution (PVP) and blood (~50 µl) were gently withdrawn and 
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discarded. If the first aspiration attempt failed, we tried to inject saline through the 
catheter. If this was successful, a second aspiration attempt was made with a clean 
syringe-tubing assembly. The catheter was then flushed with saline by short pull-
push movements. Finally, the catheter was filled with 100 µl sterile heparinized 
PVP and the pin was replaced. 
The IG catheter was rinsed with 1-2 ml sterile saline using a 10 ml filled syringe-
tubing construction. No fluids were withdrawn and no heparinized PVP was added. 
 
3.4 Blood collection procedures  
3.4.1 Blood sampling via JV catheter 
3.4.1.1 Preparation of materials 
 
The preparations for blood sampling were similar to the preparations for catheter 
flushing (see Chapter 3.3.1), but the following additional materials were used: 1 ml 
syringes (Injekt®, B.Braun, Melsungen, Germany) which were attached to long 20 
G blunted needles, 0.6 ml Eppendorf tubes, small glass tubes (Schmidlin Labor & 
Service AG, Neuheim, Switzerland) and EDTA (Titriplex 3, Merck, Art.1.08418.025) 
as an anticoagulant (100 mg dissolved in 1.0 ml distilled water). Seven µl EDTA 
suspension was put into Eppendorf tubes before blood sampling (7 µl/0.45 ml 
whole blood). 
3.4.1.2 Blood sampling procedures 
 
After flushing the catheters as described above (see Chapter 3.3.3), a small air 
bubble, about 2 mm long, was introduced into the catheter by briefly opening the 
connection between tubing and needle. This air bubble was then sent down the 
PE-tubing by gently infusing saline until it remained just inside the adapter part of 
the catheter. In this way the dead space was minimized because the air bubble 
separated the circulating blood from the infusion solution (saline). In the next step 
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100 µl blood was aspirated which was given back later with about 500 µl saline. 
The used syringe was then exchanged for a clean, dry 1ml syringe with a long 20 
G blunted needle on top and 510 µl blood was aspirated of which 350 µl were 
transferred into an Eppendorf tube (containing 7 µl EDTA solution) for later 
analysis of plasma parameters. The remaining 160 µl blood was transferred into a 
small glass tube for later analysis of serum parameters. Finally, 100 µl sterile PVP 
mixed with 1ml saline (between 2 blood sampling time points) or sterile heparinized 
PVP (after the last blood sample) was added and the pin was replaced. The 
Eppendorf tubes were immediately put on wet ice and centrifuged (8 min, 8000 
rpm, 4°C) within 20 min. The plasma was transferred into Cobas-Mira analyzer 
cups (Hoffmann La Roche, Basel) and stored at -20°C until analysis. The blood in 
the glass tubes was allowed to clot for 4-5 hours at room temperature (RT) and the 
serum was then transferred into Cobas-Mira analyzer cups. Serum was stored at 
4°C until analysis, which took place on the same day. 
 
3.4.2 Blood sampling via Cardiac puncture 
 
This technique was used for collection of a one-time single, large-volume blood 
sample (10 – 15 ml) to be used as donor blood, i.e., to replace some of the blood 
volume of experimental rats after repetitive blood sampling. The cardiac puncture 
was done under terminal inhalation anesthesia with a mixture of isoflurane in 
oxygen-dinitrogenoxide. Anesthesia was induced as described above and after 
reaching surgical tolerance a small plastic barrel containing paper towel soaked in 
isoflurane anesthetic was placed over the rat's nose during the procedure to 
ensure prolonged anesthesia. The blood sample was taken from the heart, 
preferably from the right atrium after thoracotomy. The heart was punctured with a 
21 G needle and blood was slowly withdrawn with a 10 ml syringe filled with 1.5 ml 
ACD solution (0.078 g Acidum citricum 1H2O, 0.22 g Natriumcitrat 2H2O and 0.245 
g glucose 1H2O in 10 ml; Kantonsapotheke Zurich, Switzerland). 
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3.5 Experimental diets and drugs 
 
3.5.1 Standard chow diet (see Appendix) 
 
After arrival all animals (n=10) were adapted to standard laboratory chow diet 
(Extrudate 15 mm round; No. 3436, Provimi Kliba Nafag, Kaiseraugst, Switzerland) 
with a metabolizable energy content of 13.1MJ/kg. The diet contained, by weight, 
4.5 % crude fat, 35.0 % starch, 18.5 % crude protein and 4.5 % crude fiber.  
 
3.5.2 High fat diet (see Appendix) 
 
One week after arrival, 5 rats were switched to a high fat diet (HFD: 60 % kcal 
%fat; Pellets 10 mm round; No. 2127, Provimi Kliba Nafag, Kaiseraugst, 
Switzerland) with a metabolizable energy content of 22.0 MJ/kg. The diet 
contained, by weight, 35.0 % crude fat, 1.0 % starch, 23.9 % crude protein and 4.9 
% crude fiber. The ingredients were lard, casein, maltodextrin, sucrose, cellulose, 
refined soybean oil, minerals, vitamins and amino acids. 
 
3.5.3 5 g HFD test meal including 9.1 (w/w) % C17:0 
 
In the last experiment (Experiment 3; see Chapter 3.6.3), at dark onset all animals 
received a single 5 g HFD test meal (10:00) which contained 9.1 (w/w) % of the non-
naturally-occurring FA C17:0 [454.5 mg C17:0/5 g HFD; Heptadecanoic acid 
(17:0), Fluka No. 51610, Sigma-Aldrich, Buchs, Switzerland]. This special 
experimental diet was self-made by mixing 5000 mg ground HFD with 500 mg 
C17:0 FA (solid) until a homogenous mixture was obtained, which was then 
pressed to 10-20 mm long round pellets. 
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3.5.4 Preparation of DGAT1i01 suspension 
3.5.4.1 Vehicle preparation 
 
Hydroxypropylmethylcellulose [0.5 g/100 ml] (HPMC powder; Methocel E4M, 
Colorcon Limited, Kent, England) was dispersed under continuous stirring in a 100 
ml Erlenmeyerkolben which was filled with ~30 ml hot (>80°C) milipore water. 
Thereafter, cold milipore water was added to the residual content. The mixture was 
then cooled down under continuous stirring using a magnetic stirrer. Tween 80 
solution [0.1 g/100 ml] (Sigma-Aldrich, Steinheim, Germany) was added and the 
solution was stirred again until the Tween 80 solution was dissolved. 
3.5.4.2 DGAT1-inhibitor (DGAT1i01) solution preparation 
 
0.015 g [3 mg DGAT1i01solid/5 ml Vehicle] or 0.045 g [9 mg DGAT1i01solid/5 ml 
Vehicle] DGAT1i01 solid research sample (AstraZeneca, Cheshire, United 
Kingdom) were accurately weighed in a suitable vial (25 ml Erlenmeyerkolben). 
HPMC/Tween 80 solution (see above) was then added to 90 % of the required final 
volume (25 ml) and the suspension was stirred vigorously for some minutes using 
a magnetic stirrer. Afterwards, the magnetic stirrer was removed and the additional 
HPMC/Tween 80 solution was added to the final volume. The suspension was 
continuously stirred (with a magnetic stirrer) until the experiments started. 
3.5.4.3 Handling instructions and stability 
 
The suspension of DGAT1i01 was always prepared on the day before the 
experiments and the suspension was continuously stirred at ambient temperature 
overnight to ensure adequate particle size reduction. The suspension was 
physically stable for at least seven days when stored at room temperature, 
protected from light and stirred continuously. Chemical stability was not assessed, 
but no problems were expected there based on discussions with Physical 
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Chemistry Group of AstraZeneca. There were no anticipated stability problems at 
the pH of the suspension (pH 3.03 to 3.54) over a seven day period. 
 
3.6 Experimental procedures 
 
3.6.1 Experiment 1: Effect of an IG DGAT1i01 infusion on food intake in 
Chow- and HFD-fed rats (2 trials: 3 mg/kg and 9 mg/kg) 
 
3.6.1.1 Experimental design 
 
The acute eating-inhibitory effect of DGAT1i01 was tested in 9 male SD rats 
(weight range during tests, 338-441 g and 362-489 g, respectively) which were 
equipped with a JV and IG catheter (one rat died after surgery). Rats had 
continuous ad libitum access to tap water and were fed standard laboratory chow 
(n=5; No.3436, Provimi Kliba, Kaiseraugst, Switzerland) or a high fat diet (HFD) 
(n=5; No.2127, Provimi Kliba, Kaiseraugst, Switzerland) as indicated (see Chapter 
3.5). All animals were adapted to an 8h feeding schedule (food access from 10:00 
to 18:00) for 2 weeks (wk). During these 2 wk all rats were also adapted to the 
intragastric (IG) infusion procedure with 5 ml/kg BW saline and to FI 
measurements during the dark phase (procedure see below). The experiment was 
divided into two trials (a, b). In Experiment 1a, 3 mg/kg DGAT1i01 were IG 
administered (5 ml/kg) 1h before dark onset (09:00). This design was chosen 
based on previous demonstrations of the compound’s eating-inhibitory potency by 
our collaborating group of AstraZeneca. Five days later in Experiment 1b we tested 
the effect of 9 mg/kg DGAT1i01 (5 ml/kg) under otherwise identical conditions. In 
both experiments the vehicle (HPMC/Tween 80 solution, 5 ml/kg)) was used as 
control. After IG DGAT1i01 or vehicle infusion the IG catheters were rinsed with 0.5 
ml saline.  
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3.6.1.2 Food intake measurements 
 
In Experiments 1a and 1b, cumulative food intake [g] was measured at 2, 4, 6, 8 
and 9 h after infusion (i.e., at 11:00, 13:00, 15:00, 17:00 and 18:00). Before 
experiments, all food cups were filled with approximately the same amount of chow 
(47-55 g) or HFD (28-34 g).  At each time point of food intake measurements the 
food cups were taken out of the cages, weighed (± 0.1 g) on an electronic balance 
(Mettler PM 3000, Mettler-Toledo AG, Greifensee, Switzerland) and returned to the 
cages immediately. In both parts of this experiment a within-subjects cross over 
design (in random order) was used with at least 1 d between cross over trials. 
 
3.6.1.3 Statistical analysis 
 
Food intakes at each time point were analyzed using a paired two-tailed Student t-
test (GraphPad Prism version 5.00 for windows, GraphPad Software, Inc., La Jolla, 
CA, USA). Data are expressed as means ±  SEM for n=4 (Standard Chow diet) 
and n=5 (HFD) animals, respectively. The minimal level of statistical significance 
was p < 0.05 throughout.  
 
3.6.2 Experiment 2: Effect of an IG DGAT1i01 infusion on serum and plasma 
metabolites after a 5g HFD test meal (TG, Glyc, FFA, BHB) 
 
3.6.2.1 Experimental design 
 
 Six weeks later the effect of IG DGAT1i01 infusion on serum and plasma 
metabolites was tested in the same 8 male SD rats (weight range during test, 462-
642 g; one rat died during the flushing procedure) which were equipped with JV 
and IG catheters. All animals were adapted to HFD for at least 4 wk and 
furthermore adapted to the IG infusion procedure with 5 ml/kg BW saline for 
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several times. Four days prior to the experiment we changed the feeding schedule 
(food access from 10:00 to 18:00) as follows: A 5 g HFD test meal was offered at 
the beginning of the dark phase (10:00) and access to the HFD was reestablished 
4 h later (14:00) until 18:00. DGAT1i01 (9 mg/kg BW) or vehicle (see above) was 
IG infused (5 ml/kg) 1h before dark onset (09:00) and the catheter was rinsed as 
described above. Blood samples were taken via the JV catheter (see Chapter 
3.4.1.2) at 08:45 (shortly before IG infusion), 11:00 (2 h after IG infusion, 1 h after 
test meal), 12:00 (3 h after IG infusion, 2 h after test meal) and 14:00 (5 h after IG 
infusion, 4 h after test meal). Serum and plasma samples were prepared as 
described above and stored at -20°C until analysis, which was usually done on the 
same day. All animals received 1.5 ml donor blood (preparation see Chapter 3.4.2) 
after the last blood sampling at 14:00. The experiment was designed as a within-
subjects cross over test with the treatments given in random order and with at least 
2 days between trials. 
3.6.2.2 Biochemical assays of serum and plasma metabolites 
 
We determined serum triglycerides (TG), plasma glycerol (Glyc), free fatty acids 
(FFA) and β-Hydroxybutyrat (BHB), concentrations using standard colorimetric and 
enzymatic methods adapted for the Cobas MIRA® autoanalyzer (Hoffman 
LaRoche, Basel, Switzerland). 
 
3.6.2.3 Data collection and statistical analysis 
 
Serum and plasma parameters were analyzed with two-way repeated measures 
ANOVA (SAS 9.1, SAS Institute, Cary NC, USA) with subjects (animals) and drug 
treatment (DGAT1i01, vehicle) as factors and time points of blood sampling as 
repeated measures. Significant ANOVA effects were followed up by planned 
pairwise comparisons with the Bonferroni-Holm test [HOLM, 1978]. To identify 
outliers, data were converted to standard scores using the medians and median 
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absolute deviates x 1.48 (which estimates the standard deviation), and values > 
2.57 (i.e., P < 0.01) were excluded. Differences were considered significant when 
P < 0.05. Graphs were generated using GraphPad Prism (GraphPad Prism version 
5.00 for windows, GraphPad Software, Inc., La Jolla, CA, USA). Data are 
expressed as means ±  SEM for n=8 and n=7, respectively.  
 
3.6.3 Experiment 3: Effect of DGAT1i01 on fatty acid oxidation in small 
intestinal enterocytes after a 5g HFD+C17:0 test meal 
 
3.6.3.1 Experimental design 
 
The effect of IG DGAT1i01 infusion on fatty acid oxidation (FAO) in small intestinal 
enterocytes was tested in 16 male SD rats (8 rats from the previous experiment, 
weight range during experiment 467-645 g, and 8 additional rats (weight range 
during the experiment 548-600 g), which were housed and treated similarly). All 
animals were equipped with IG catheters and adapted to the IG infusion procedure 
with 5 ml/kg BW saline. Furthermore, all animals were adapted to the HFD for at 
least 3 weeks. Four days prior to the experiment we changed the feeding schedule 
(food access from 10:00 to 18:00) as in Experiment 2, i.e., a 5 g HFD test meal 
was offered at the beginning of the dark phase (10:00) after 16 h of food 
deprivation. At 14:00 food access to HFD was reestablished until 18:00. DGAT1i01 
(9 mg/kg in 5 ml) or vehicle (5 ml/kg) (n=8, each) was administered IG 1h before 
dark onset (09:00) and the catheters were flushed as described. On the day of the 
Experiment a 5 g HFD test meal including 9.1 (w/w) % C17:0 (see Chapter 3.5.3) 
was offered to all animals simultaneously at the time of usual food access (dark 
onset). Two hours later (12:00), the first rat was sacrificed and tissue samples were 
taken out of the small intestine as described below. After 20 min the tissue 
sampling was finished and the next rat was prepared for sacrificing. The 
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experiment was designed as a random cross over test which was subdivided in 4 
days (4 rats per day) within 2 weeks. 
 
3.6.3.2 Tissue sampling and preparation – A scraping technique 
 
(According to [DIETSCHY et al., 1965] modified) 
Each animal was anesthetized with isoflurane and the abdominal cavity was 
opened. The first 30cm of the small intestine were excised and divided into 3 parts 
of about 10cm length, each. The 3 segments were immediately placed in ice-cold 
0.9% saline and labeled (A = 0-10, B = 10-20, C = 20-30 cm; from proximal to 
distal). The bowel segments were then cut open longitudinally along the 
antimesenteric border and the intestinal contents were thoroughly removed from 
each segment by flushing with fresh ice-cold 0.9 % saline. Thereafter the segments 
were swabbed on a cellulose wadding swab (Cellodent®) to remove most of the 
saline, and were laid on a plastic Petri dish with the mucosal side up. The Petri 
dishes were kept on ice during the preparation. The mucosa was scraped off gently 
with the edge of a glass microscope slide, attention being paid to not taking along 
fat tissue and to leaving the denuded smooth muscle layer intact. The mucosal 
scrapings were homogenized with the glass slide on the Petri dish and 200 µl of 
the homogenate was pipetted into a chilled round bottom Eppendorf tube and 
subsequently stored at -80°C until fatty acid analysis by gas chromatography. 
 
3.6.3.3 Lipid extraction from small intestine mucosa sample 
 
Fatty acids were extracted from the small intestinal mucosa samples as described 
elsewhere ([FOLCH et al., 1957] and modified by Mansouri and Koss [MANSOURI 
et al., 2008b]. Briefly, the 200 µl sample was thawed at room temperature, mixed 
and homogenized in 1.0 ml methanol (Fluka No.65548, Sigma-Aldrich, Buchs, 
Switzerland) using the polytron (Kinematica AG, Littau, Switzerland. The mixture 
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was then transferred into a glass tube, which was degreased with hexan (Sigma-
Aldrich, Buchs, Switzerland) and sealed with a Teflon screw cap. Thereafter, 2 ml 
of chloroform (Fluka No.25697, Sigma-Aldrich, Buchs, Switzerland) were added 
and the mixture was incubated overnight (>12 h) at 50°C under continuous 
shaking. Then the solution was washed with 3 ml of 0.9 % saline and centrifuged 
(1000 x g, 5 min) to separate the two phases (chloroform and water). The lipid-
containing chloroform phase (lower) was then transferred into a new glass tube; 
special care was taken not to transfer water or cell debris. 
 
3.6.3.4 Acid-catalyzed transesterification with methanol  
 
(According to [LEWIS et al., 2000] modified) 
The chloroform phase was further used and 3 ml of 10% v/v sulfuric acid (Riedel-
de-Haenen No.30723, Sigma-Aldrich, Buchs, Switzerland) in methanol (90 ml 
methanol+10 ml sulfuric acid) were added. The reaction mixture was then 
incubated at 50°C overnight in a tightly closed tube. On the next day the mixture 
was cooled down to room temperature and washed with a large volume of 2 M 
NaCl. After washing, the mixture was centrifuged again (1000 x g, 5 min) to 
recover the chloroform phase. The lipid-containing chloroform phase was then 
transferred again into a new glass tube and washed a second time with 2 M NaCl. 
Finally, the upper phase (~2.5 ml) was discarded and the chloroform phase was 
transferred into an auto sampler vial for gas chromatography. 
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3.6.3.5 Preparation of a FAME standard and controls 
 
A FAME (fatty acid methyl ester) standard was generated with C17:0, C15:0, 
C13:0 and C11:0 fatty acids (FAs). Ten mg of each fatty acid was weighed in a 
glass tube and 160 µl of water was added. This mixture was then treated in the 
same way as the samples (see above; Chapters 3.6.3.3 and 3.6.3.4). Before the 
chloroform phase was transferred into an auto sampler vial it was diluted with 
chloroform 1:1000 (0.01 mg of each FA) and 1:100 (0.1 mg of each FA). For the 
preparation of the controls, 1000 mg of the normal HFD and 1000  mg of the HFD 
+ 9.1 % C17:0 (Preparation see above; Chap. 3.5.3) were homogenized in 5 ml of 
methanol using the polytron. 200 µl of this homogenate were used instead of the 
samples (~36 mg HFD and 32.8 mg HF + 3.2 mg C17:0 respectively) and were 
treated in the same way. Prior to the final step the chloroform phase was also 
diluted with chloroform (1:1000 (0.01 mg of each FA) and 1:100 (0.1 mg of each 
FA). 
 
3.6.3.6 Fatty acids analysis (Gas chromatography) 
 
The FA profile of the liquid containing chloroform phase was analyzed by gas 
chromatography using a gas chromatograph (HP 6890, Hewlett-Packard, 
Philadelphia, PA, USA) equipped with a Supelcowax-10 column (30 m x 0.32 mm, 
0.25 m; Supelco Inc., Bellefonte, PA, USA). 
 
3.6.3.7 Data collection and statistical analysis 
 
Data were analyzed using a paired two-tailed Student t-test (GraphPad Prism 
version 5.00 for windows, GraphPad Software, Inc., La Jolla, CA, USA) and values 
are expressed as means ±  SEM for treatment (n=8) and control (n=8). Differences 
were considered significant when P < 0.05. 
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4 RESULTS 
 
4.1 Experiment 1: Effect of IG DGAT1i01 infusions on food 
intake 
4.1.1 Experiment 1a 
IG infusions of DGAT1i01 (3 mg/kg BW) significantly decreased cumulative food 
intake during the dark phase (10:00 – 18:00) at 6 h (~16 %) and 8 h (~18%) after 
infusion onset (9:00) in HFD-fed rats (n=5) compared to control. The food intake in 
chow-fed rats (n=4) was not significantly affected by the IG DGAT1i01 infusion 
(see Figure 4.1). 
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Figure 4.1: Effects of IG DGAT1i01 (3mg/kg BW) or Vehicle (HPMC/Tween 80 solution) 
infusion on cumulative food intake [kJ] in HFD-fed rats (A) and Chow-fed rats (B). 
All animals were food deprived for 16 h and re-fed at dark onset (10:00). The infusions (5ml/kg) 
were done 1h before dark onset (9:00). Data are means ± SEM. * Significantly lower than 
corresponding control (paired t-test, *p < 0.05; **p < 0.01).  
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4.1.2 Experiment 1b 
 
IG infusions of DGAT1i01 (9 mg/kg BW) significantly decreased cumulative food 
intake during the dark phase (10:00 – 18:00) at 4 h (23.7 %), 6 h (17.7 %), 8 h 
(21.0%) and 9 h (22.5 %) after infusion onset compared to control. The food intake 
in chow-fed rats (n=4) was not significantly affected by the IG DGAT1i01 infusion 
(see Figure 4.2). 
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Figure 4.2: Effects of IG DGAT1i01 (9mg/kg BW) or Vehicle (HPMC/Tween 80 solution) IG 
infusion on cumulative food intake [kJ] in HFD-fed rats (A) and Chow-fed rats (B). 
All animals were food deprived for 16h and re-fed at dark onset (10:00). The infusions (5 ml/kg) 
were done 1h before dark onset (9:00). Data are means ± SEM. * Significantly lower than 
corresponding control (paired t-test, *p < 0.05; **p < 0.01). 
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4.2 Experiment 2: Effect of IG DGAT1i01 infusions on serum and 
plasma metabolites 
 
The serum triglyceride (TG) (A), plasma free glycerol (Glyc) (B) and free fatty acid 
(FFA) (C) levels increased (significantly higher than baseline at 3h) and the plasma 
BHB (D) levels decreased (significantly lower than baseline at 5 h) in the control 
(vehicle) condition after the 5 g HFD meal at dark on set in 16 h-fasted rats (n=8 
and n=7, respectively). IG DGAT1i01 (9 mg/kg BW) infusions (1h before dark 
onset) blunted these changes (A, B, C, D). Serum TG (see Figure 4.3 (A)) as well 
as plasma free glycerol and FFA levels (see Figure 4.3 (B and C)) were 
significantly lower  3 h after DGAT1i01 infusion than after vehicle infusion (F3/36 = 
8.84, p < 0.001) (A), F3/35 = 9.25, p < 0.001 (B) and F3/34 = 4.07, p < 0.05 (C), 
respectively), whereas plasma BHB levels (D) were significantly higher than after 
vehicle at 5 h after infusion (F3/15 = 9.43, p = 0.001; see Figure 4.3 (D)). In addition, 
serum TG levels 2 h after DGAT1i01 infusion were significantly lower than at 
baseline (F3/36 = 8.84, P < 0.001 (A)). There was no significant difference in plasma 
levels of Glyc, FFA, and BHB at 3 h and 5 h after DGAT1i01 infusion compared to 
baseline (see Figure 4.3 (B, C, D)). 
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Figure 4.3: Effects of DGAT1i01 (9 mg/kg BW) or Vehicle (Veh; HPMC/Tween 80 solution) IG 
infusion on serum and plasma metabolites in 16-h food-deprived HFD-fed rats. 
The infusions were done 1 h before dark onset (09:00) with a dose volume of 5 ml/kg BW. At 
dark onset (10:00) rats had access to a meal of 5 g HFD for 1 h. Each time point represents 
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the mean ± SEM of n=8 (A, B, D) or n=7 (C) animals. # Significantly different from the 
corresponding vehicle condition; + Significantly lower than baseline levels; § Significantly 
different from baseline levels (A, B, C, D) (Bonferroni-Holm post-hoc test after significant 
ANOVA). A: Serum triglyceride (TG); B: Plasma free glycerol (Glyc); C: Plasma free fatty 
acids (FFA); D: Plasma β-Hydroxybutyrat (BHB) 
 
 
 
4.3 Experiment 3: Effect of DGAT1i01 IG infusion on FAO in 
small intestinal enterocytes after a 5 g HFD test meal 
including 9.1 (w/w) % C17:0 FA 
 
The measured C15:0 FA content in the small intestine mucosa sections (A, B, and 
C), which was generated by mucosal β-oxidation of C17:0 FA, did not differ 
significantly from vehicle treatment (see Figure 4.4). IG DGAT1i01 (9 mg/kg BW) 
infusions (5 ml/kg BW; 1 h prior to dark onset) did not significantly affect FAO in 
small intestinal enterocytes 3 h after infusions onset in 16-h-fasted and re-feed rats 
(5 g HFD test meal including 9.1(w/w) % C17:0). 
 
 
 
Results
 
   
68 
 
 
C15:0 fatty acids contents
in small intestine mucosa samples
A B C
0
5
10
15
20
Vehicle (n=8)
DGAT1i (n=8)
Small Intestine Section
%
 C
15
:0
 
 
Figure 4.4: C15:0 fatty acids contents of small intestine mucosa after IG DGAT1i01 (9mg/kg 
BW) or Vehicle infusion. 
C15:0 fatty acid contents of small intestine mucosa samples (A, B, C) are expressed as percentage 
(%) of the total amount of FAs C17:0 + C15:0 (100%). A = section most proximal and C = section 
most distal to the stomach; each section about 10 cm. Each bar represents the mean ± SEM of 
eight rats (Student’s t-test). 
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5 DISCUSSION 
 
5.1 Experiment 1: Effect of IG DGAT1i01 infusions (3 and 9 
mg/kg BW) on food intake in Chow- and HFD-fed rats 
 
This study was designed to test the hypothesis that an acute IG DGAT1 inhibitor 
(DGAT1i01) infusion inhibits FI in rats. The results confirmed the hypothesis, 
demonstrating that IG infused DGAT1i01 (9 mg/kg BW and 3 mg/kg BW, 
respectively) reduced food intake in HFD-fed rats starting at 4 or 6 hours after 
administration, but not in chow-fed rats. These results indicate that the fat content 
of the diet is crucial for this eating-inhibitory effect of DGAT1i01; given the primary 
localization of DGAT, the results are consistent with the idea that some aspect of 
intestinal epithelial cell fat handling is involved. Thus, it appears that a shift of 
intracellular fat metabolism from TG synthesis to fatty acid oxidation could be 
involved, but no firm conclusion can be drawn based on the present data. 
Furthermore, the eating-inhibitory effect of DGAT1i01 appears to be dose-
dependent, but a direct comparison of the effectiveness of the two doses is not 
possible because they were administered in two different trials. Interestingly, 
however, our collaborating group at AstraZeneca (AZ) observed that the oral 
administration of DGAT1i01 (supramaximal dose of 30 mg/kg BW) led to a rapid 
onset inhibition of eating at 2 hours after administration in 20 h fasted rats which 
were also adapted to a HFD. This demonstrates that the eating-inhibitory effect is 
not limited to our experimental design, but may differ depending on the exact 
experimental conditions. At present, however, it remains unclear whether 
DGAT1i01 reduces food intake in both experimental paradigms by exactly the 
same mechanism. 
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5.2 Experiment 2: Effect of IG DGAT1i01 infusions on serum and 
plasma metabolites 
 
The aim of this study was to investigate the effects of an acute IG DGAT1i01 
infusion on circulating metabolites in rats. We determined serum TG, plasma 
glycerol, FFA and BHB in rats which were fasted for 16 h and re-fed with a 5 g 
HFD test meal 1 h after administration of DGAT1i01 (9 mg/kg BW) or vehicle. As 
expected, serum TG and plasma glycerol levels increased in control animals after 
the HFD meal. Further, we could show that DGAT1i01 eliminated this increase and 
even decreased TG and glycerol levels. This decrease in both metabolites was 
unexpected and is hard to explain, if the action of DGAT1i01 is limited to 
enterocytes. We speculated that DGAT1i01 may also have some effect on the 
liver, inhibiting hepatic TG synthesis and thereby enhancing hepatic FAO. We 
therefore checked whether plasma β-hydroxybutyrate (BHB) levels were affected. 
Interestingly, our results showed that DGAT1i01 administration resulted in a 
significant increase in plasma BHB, which appears to confirm our hypothesis of an 
additional hepatic action. We could further show that plasma FFA levels after 
DGAT1i01 infusion did not increase after the test meal, as after vehicle infusion, 
but rather decreased. This could be due to a decrease in LPL-mediated TG 
hydrolysis and uptake of FFA and glycerol into tissues that is secondary to the 
decreased circulating TG levels resulting from decreased intestinal TG synthesis. 
In general, however, our rat model (chronically eating a 60 % HDF for more than 
two months) appears to be hypertriglyceridemic (serum TGs ~2 mM). 
In summary, these results suggest that inhibition of DGAT1 and, hence, interfering 
with its role in intestinal fat absorption has metabolic effects that may contribute to 
the eating-inhibitory effect observed in Experiment 1. Moreover, the results suggest 
that DGAT1 inhibition may also occur in the liver, where TGs are synthesized. 
Further investigations are necessary to critically examine the hypothesis of 
enhanced enterocyte FAO in response to DGAT1i01. 
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5.3 Experiment 3: Effect of DGAT1i01 IG infusion on FAO in 
small intestinal enterocytes after a 5g HFD test meal 
including 9.1 (w/w) % C17:0 FA 
 
 
One possible explanation for the behavioral results in Experiment 1 is that 
DGAT1i01 administration reduced food intake by indirectly stimulating intestinal 
epithelial cell fatty acid oxidation. This has recently been hypothesized to be one 
metabolic mechanism controlling eating [LANGHANS, 2008]. There is also 
evidence that intestinal FAO is increased when mice are adapted to a diet enriched 
with PUFAs or TGs when compared to diets without additional fat [MORI et al., 
2007]. Also, men showed a lower respiratory quotient (RQ; CO2 expired/O2 
consumed) after a HF meal compared to an isocaloric low fat meal, indicating that 
high fat intake increases fat oxidation [SURINA et al., 1993]. Based on prior work 
by AZ, DGAT1 inhibition also lowers RQ in low-fat and chow-fed C57BL/6 mice 
when compared to controls, which suggests an enhanced whole body FAO. 
Therefore, the aim of this experiment was to determine whether FAO in small 
intestinal mucosa samples from HFD adapted rats was enhanced after an IG 
DGAT1i01 infusion (9 mg/kg BW) when compared to vehicle infused rats. 
However, under the conditions tested, we could not find a significant difference in 
intestinal epithelial cell fatty acid oxidation after DGAT1i01 and vehicle 
administration. But there seemed to be a tendency for increased FAO, in particular 
in the most distal intestine mucosa sections. Based on our findings, it could be 
speculated that DGAT1 inhibition in enterocytes may enhance mucosal FAO and 
therefore inhibit eating. To revisit this possible effect of DGAT1 inhibition on 
enterocyte FAO we have to optimize our techniques for mucosa isolation and FAO 
measurement, and we have to reconsider the time point of small intestine tissue 
sampling. Furthermore, we should turn our attention more to the mid jejunum 
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because our data suggest that FAO is highest in the section most distal to the 
stomach (Section C; last 10 cm of the intestine excision). 
  General discussion 
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6 GENERAL DISCUSSION 
 
 
DGAT1 is one of two known DGAT enzymes that catalyzes the final and only 
committed step in TG synthesis (reviewed in [FARESE, JR. et al., 2000]. Many 
studies used DGAT1-deficient mice to investigate the biological function of DGAT1 
[BUHMAN et al., 2002; CHEN et al., 2002b; CHEN et al., 2002c; CHEN, 2006; 
FARESE, JR. et al., 2000; SMITH et al., 2000], but the effects of DGAT1 deficiency 
on FI have not been systematically examined yet. Furthermore, currently only little 
is known about synthetic DGAT1 inhibitors and their effects on behavior. 
Therefore, this is the first study that begins to thoroughly investigate the effect of a 
molecular DGAT1 inhibitor (generously provided by AstraZeneca) on food intake 
and that tries to identify the underlying mechanism of action. 
 
In summary, the results of our three experiments show that an intragastrically 
administrated DGAT1 inhibitor 1) decreases food intake in rats when the dietary fat 
content is high and 2) induces metabolic effects that are consistent with the 
hypothesis that a shift from TG synthesis to fatty acid oxidation is the underlying 
mechanism of the observed eating-inhibitory effect. As DGAT1 is primarily located 
in enterocytes, our  data are consistent with previous findings (see [LANGHANS, 
2008]Langhans, 2008) in suggesting that it is not primarily hepatic fatty acid 
oxidation that affects food intake. Rather, fatty acid oxidation in enterocytes 
appears to be affected by DGAT1i01 and may thus contribute to the control of 
eating.  
 
This working hypothesis is a novel concept for the metabolic control of eating 
because so far all hypotheses explaining the effects of peripheral metabolism on 
food intake focused on the liver. Several considerations make the intestine, and in 
particular the intestinal epithelial cells in fact a similarly – or even more – likely site 
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where metabolic events might be sensed by the body to affect eating. In general it 
is known that enterocytes use glutamine, glucose and ketone bodies as energy 
source, but there is also evidence that enterocytes oxidize fatty acids in addition to 
the other substrates (reviewed by [LANGHANS, 2008]).  
Furthermore, there are vagal afferents present that are close to enterocytes and 
may therefore be in the position to convey sensory information from these cells to 
the CNS [BERTHOUD et al., 2004]. Recently, it has been demonstrated that intact 
vagal afferents are necessary for the stimulation of eating after intraperitoneal 
injection of the fatty acid oxidation inhibitor mercaptoacetate in rats [BRANDT et 
al., 2007]. Of course, there are several open questions regarding the idea that 
vagal afferents can sense metabolic changes in enterocytes and generate signals 
that affect eating. Foremost, the transduction mechanism of the signal from 
enterocytes to vagal afferents is unknown. Another remaining question is whether 
the sensing mechanism is specific for fatty acid oxidation or whether it also senses 
the utilization of other nutrients, such as glucose or amino acids.  
 
Therefore, further studies are necessary to critically address these open issues 
before the idea of an eating control mechanism based on changes in enterocyte 
fatty acid oxidation (or metabolism) can be adopted. 
 
In any case, however, the present findings might provide clues to an understanding 
of the mechanisms underlying the effects of a DGAT1-inhibitor on lipid metabolism 
and thus help to elucidate the possible role of intestinal FA catabolism in the 
control of food intake. 
  Summary 
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7 SUMMARY 
 
This thesis addresses the effects of a molecular Acyl CoA:diacylglycerol 
acyltransferase 1 (DGAT 1; a key enzyme in the TG synthesis) inhibitor on food 
intake and its underlying mechanism of action. The focus was to investigate 
whether the eating inhibition in response to pharmacological DGAT1 inhibition is 
due to enhanced fatty acid oxidation in small intestinal enterocytes. 
In the first experiment, we investigated the effect of an acute IG DGAT1-inhibitor 
(DGAT1i01) infusion on FI 16 h-fasted chow-fed or HFD-fed rats (n=9). Doses of 3 
and 9 mg/kg DGAT1-inhibitor significantly reduced food intake in HFD-fed rats (18 
% and 21 %, respectively, 8 h post infusion), but not in chow-fed rats.  
In the second experiment we could show that IG DGAT1i01 infusion (9 mg/kg) had 
an effect on serum TG, plasma Glyc, FFA and BHB levels after a 5 g HFD test 
meal in 16 h-fasted rats (n=8). Serum TG, plasma Glyc and FFA levels increased 
after the HFD meal in response to vehicle infusion, whereas the DGAT1i01 
decreased TG, Glyc and FFA levels. Also, DGAT1i01 increased plasma BHB 
levels compared to vehicle.  
In the third experiment the effect of IG DGAT1i01 (9 mg/kg) infusion on mucosal 
FAO in 16 h-fasted and re-fed rats (n=16) (5 g HFD test meal including 9.1(w/w) % 
C17:0) was investigated. However, under the conditions tested, we could not find a 
significant difference in intestinal epithelial cell FAO after DGAT1i01 and vehicle 
administration; there seemed to be a tendency for increased FAO, in particular in 
the most distal intestine mucosa sections. 
In conclusion, these results show than an intragastrically administrated DGAT1-
inhibitor decreases food intake in rats when the dietary fat content is high. The 
resulting metabolic effects are consistent with the hypothesis that a shift from TG 
synthesis to FAO in enterocytes and, perhaps, in liver is the underlying mechanism 
of the observed eating-inhibitory effect. 
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8 ZUSAMMENFASSUNG 
 
Die vorliegende Diplomarbeit untersucht den Einfluss eines molekularen Acyl 
CoA:diacylglycerol acyltransferase 1 (DGAT1; ein Schlüsselenzym in der TG 
Synthese) Inhibitors auf die Nahrungsaufnahme und die involvierten 
Mechanismen. Der Schwerpunkt lag dabei auf der Frage, ob die Hemmung der 
Nahrungsaufnahme durch den Inhibitor auf einer Stimulation der 
Fettsäurenoxidation in den Darmepithelzellen beruht. In der ersten Studie wurde 
der Effekt einer akuten intragastralen (IG) Infusion von DGAT1-Inhibitor 
(DGAT1i01) auf den Verzehr nach 16 h Futterentzug bei Ratten untersucht, die mit 
einer Standarddiät oder einer Hochfettdiät (HFD) gefüttert wurden (n=9). Dosen 
von 3 und 9 mg/kg  DGAT1i01 reduzierten den Verzehr bei Fütterung mit der HFD 
nicht jedoch bei Fütterung mit der Standarddiät signifikant (18 bzw. 21 %). Im 
zweiten Experiment konnten wir zeigen, dass die IG Infusion von DGAT1i01 (9 
mg/kg) nach einer 5 g Testmahlzeit und nach 16 h Futterentzug auch die 
Serumkonzentration von TG sowie die Plasmakonzentrationen von Glyc, FFA und 
BHB beeinflusste. TG im Serum sowie Glyc und FFA im Plasma stiegen nach 
Kontrollinfusion an und fielen nach DGAT1i01 Infusion ab. Ferner erhöhte die 
DGAT i01-Infusion die Plasmakonzentration von BHB. Im dritten Experiment wurde 
nach 16 Stunden Futterentzug der Einfluss von IG DGAT1i01 (9 mg/kg) auf die 
Fettäurenoxidation in Darmepithelzellen überprüft. Die HFD-Testmahlzeit  enthielt 
dazu 9.1 (w/w) % C17:0. Unter diesen Bedingungen liess sich kein signifikanter 
Effekt nachweisen, lediglich in dem am weitesten distal gelegenen Darmabschnitt 
war die Fettsäurenoxidation tendenziell erhöht. Insgesamt zeigen diese Daten, 
dass IG DGAT1i01 die Nahrungsaufnahme reduziert, wenn der Fettgehalt der Diät 
hoch ist. Die beobachteten metabolischen Effekte sind konsistent mit der 
Hypothese, dass eine Verschiebung von TG-Synthese zu Fettsäurenoxidation in 
Enterozyten und vielleicht auch in der Leber zu der beobachteten 
Verzehrsreduktion beiträgt. 
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